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Abstract 
 
Consent forms serve as evidence of permissions granted by patients for clinical 
procedures. As the recognized value of biospecimens and health data increases, many clinical 
consent forms also seek permission from patients or their legally authorized representative to 
reuse residual clinical biospecimens and health data for secondary purposes, such as research. 
Such permissions are also granted by the government, which regulates how residual clinical 
biospecimens may be reused with or without consent. 
There is a need for increasingly capable information systems to facilitate discovery, 
access, and responsible reuse of residual clinical biospecimens and health data in accordance 
with these permissions. Semantic web technologies, especially ontologies, hold great promise as 
infrastructure for scalable, semantically interoperable approaches in healthcare and research. 
While there are many published ontologies for the biomedical domain, there is not yet 
ontological representation of the permissions relevant for reuse of residual clinical biospecimens 
and health data.  
The Informed Consent Ontology (ICO), originally designed for representing consent in 
research procedures, may already contain core classes necessary for representing clinical consent 
processes. However, formal evaluation is needed to make this determination and to extend the 
ontology to cover the new domain. This dissertation focuses on identifying the necessary 
information required for facilitating responsible reuse of residual clinical biospecimens and 
health data, and evaluating its representation within ICO. The questions guiding these studies 
include: 
xiv 
 
• RQ1) What is the necessary information regarding permissions for facilitating 
responsible reuse of residual clinical biospecimens and health data?  
• RQ2) How well does the Informed Consent Ontology represent the identified 
information regarding permissions and obligations for reuse of residual clinical 
biospecimens and health data? 
We performed three sequential studies to answer these questions. First, we conducted a 
scoping review to identify regulations and norms that bear authority or give guidance over reuse 
of residual clinical biospecimens and health data in the US, the permissions by which reuse of 
residual clinical biospecimens and health data may occur, and key issues that must be considered 
when interpreting these regulations and norms. Second, we developed and tested an annotation 
scheme to identify permissions within clinical consent forms. Lastly, we used these findings as 
source data for bottom-up modelling and evaluation of ICO for representation of this new 
domain. We found considerable overlap in classes already in ICO and those necessary for 
representing permissions to reuse residual clinical biospecimens and health data. However, we 
also identified more than fifty classes that should be added to or imported into ICO.  
These efforts provide a foundation for comprehensively representing permissions to reuse 
residual clinical biospecimens and health data. Such representation fills a critical gap for 
developing applications which safeguard biospecimen resources and enable querying based on 
their permissions for use. By modeling information about permissions in an ontology, the 
heterogeneity of these permissions at a range of levels (e.g., federal regulations, consent forms) 
can be richly represented using entity-relationship links and embedded rules of inference and 
inheritance. Furthermore, by developing this content in ICO, missing content will be added to the 
Open Biological and Biomedical Ontology (OBO) Foundry, enabling use alongside other widely 
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adopted ontologies and providing a valuable resource for biospecimen and information 
management. These methods may also serve as a model for domain experts to interact with 
ontology development communities to improve ontologies and address gaps which hinder 
successful uptake. 
 
 1 
Chapter 1 Introduction 
 
1. Background 
Patients commonly sign consent forms for a range of diagnostic and therapeutic clinical 
procedures. Upon signing, these forms become artifacts of administrative and legal significance. 
Signatures serve as indicators that an informed consent process has occurred between the 
patients (or their legally authorized representatives) and clinicians, and that patients are willing 
to participate in and grant permission for the procedures included on the form and discussed with 
them by their provider.[1,2] The forms become valid as a legal document of permission upon 
signature by all involved parties.[3] 
Clinical procedures often include collection of blood, body fluids, or tissues (i.e., 
biospecimens) from the patients’ bodies. Once the clinical indication for collection is complete, 
remaining portions of these biospecimens may be discarded. However, the recognized value of 
residual clinical biospecimens and health data is increasing, largely related to expanding methods 
for analyzing and aggregating genomic data and associated clinical data. As a result, clinical 
consent forms may also include statements seeking permission to save residual clinical 
biospecimens and health data for secondary purposes.[4] These material and information 
resources have a range of applications for reuse, including genetic and molecular research,[5] 
commercial development for products such as of pharmaceuticals and medical devices,[6] 
precision medicine,[7] and population-health research.[8] Progress in these areas depends on 
accessing massive collections of biospecimens and health data from as many people as possible, 
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with as much heterogeneity as possible.[9] This suggests the need to maximize accessibility and 
sharing of biospecimens and their associated data for multiple uses.[10] 
However, the need for biospecimens alone does not warrant their sharing or release. 
Authority over residual clinical biospecimens and permissions granted for them originate from 
the donors of the specimens, the institutions involved in collecting them, and relevant regulatory 
bodies, including but not limited to the federal government and overseeing organizations. As an 
added layer of complexity, regulation of biospecimen reuse varies based on the context of the 
biospecimens’ collection, such as during clinical care or for primary research use.[4,11] 
Regardless of whether consent documents were for health care or research, we lack 
methods to support automated or semi-automated querying of permissions for reuse of 
biospecimens and data, based on a foundation of contemporary semantic technologies. It is not 
uncommon for biorepositories to archive hundreds of thousands of specimens,[12] which vary in 
terms of the consented (i.e., permitted) modes of reuse. Retrieving and reviewing this 
information about permissions using the actual or scanned image of original consent form is 
time-intensive and requires case-by-case review by some human actor who must understand the 
complex interactions of the multiple sources of authority over reuse of these biospecimens. As 
such, manual review lacks scalability and may be prone to inconsistencies or error. Presently, 
when this information is represented in biorepositories’ information systems, it is “locked in” 
proprietary and/or non-standard formats.[13] These burdens are further captured in the 
suggestion that, “methods for handling informed consent decisions at best remain non-
interoperable, and at worst are wholly paper-based.”[14] eConsent forms do not yet address the 
need for interoperable queries of permissions within the consent document. And while the Office 
of the National Coordination for Health Information Technology has called for standards-based 
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approaches to expressing consent,[15] the focus is on documents, not the permissions within the 
consent documents. 
There is a need for increasingly capable information systems to facilitate the capture, 
discovery, access, and responsible reuse of stored biospecimens and data, whether from research 
or clinical processes, retaining permission information expressed in signed consent documents. 
Semantic web technologies, and especially ontologies, hold great promise as infrastructure for 
scalable, semantically interoperable approaches in healthcare and research.[16] Ontologies are 
classically defined as common vocabularies to share information in a domain which “includes 
machine-interpretable definitions of basic concepts in the domain and relations among 
them.”[17] Ontologies thereby enable integration of multiple bodies of data through ‘annotating’ 
or mapping their individual fields to the structural elements of a common , shared ontology, as 
well as interoperability at the level of software interfaces, without manual mapping.  
Many ontologies for the biomedical domain are published and in-use.[18] A study to 
identify the minimum metadata necessary for biobank information systems to share 
biospecimens data called out the need for ontologies which represent the “ethical standards under 
which the samples are collected, any restrictions on research use, and access requirements to the 
samples to expressing the permissions for reuse.”[19] Such work has been started through 
development of the Informed Consent Ontology, which was originally designed for representing 
consent in research procedures.[20] However, there is not yet ontological representation of the 
permissions relevant for reuse residual clinical biospecimens and health data, i.e., those which 
were collected during clinical care processes. 
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2. Research Questions and Specific Aims 
This dissertation focuses on (a) exploring the necessary information regarding 
permissions to reuse of residual clinical biospecimens and health data, and (b) evaluating the 
representation of this information within an ontology of informed consent (ICO).  
2.1. Research Question 1. What is the necessary information regarding permissions for 
facilitating responsible reuse of residual clinical biospecimens and health data?  
Specific Aim 1: 
• 1a: To identify relevant federal regulations and norms (e.g., best practices, 
guidance documents) that bear authority or give guidance over reuse of residual 
clinical biospecimens and health data in the US.  
• 1b: To gather domain experts’ interpretations of the permissions by which reuse 
of residual clinical biospecimens and health data may occur. 
• 1c: To gather domain experts’ interpretations of the key issues and concepts – 
including the overlap, congruency, and gaps – that must be considered when 
interpreting regulations and norms for reuse of residual clinical biospecimens 
and health data.  
We conducted a scoping review to identify sources of regulation or guidance that bear 
authority on reuse of residual clinical biospecimens and health data. To obtain a broad array of 
expert perspectives on permissions for residual clinical biospecimen and health data reuse, we 
searched a range of biomedical, legal, and health ethics and policy databases.  
Specific Aim 2: To develop and test an annotation scheme for identifying permissions 
within clinical consent forms. We followed Pustejovsky and colleagues’ MAMA (Model-
Annotate-Model-Annotate) cycle as the method for developing and refining our annotation 
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scheme, and evaluated our annotation scheme instructions using a subset of the data and revised 
the annotation scheme based on our findings. 
2.2. Research Question 2. How well does the Informed Consent Ontology (which was 
designed for research procedures) represent the identified information from aims 1 and 2 
regarding permissions and obligations for sharing and use of specimens and data collected in 
the context of clinical procedures? 
 Specific Aim 3: To evaluate ICO for representing clinical permissions, focusing 
on reuse of residual clinical biospecimens and health data. Evaluation of the ontology was 
performed using methods for evaluating ontologies from the literature during extension to new 
domains.[21] This evaluation focuses on domain-specific knowledge representation rather than a 
computational structure or operational requirements.  
3. Significance 
In completing these aims, this dissertation identifies necessary content for permissions to 
reuse residual clinical biospecimens and health data, and systematically evaluates the coverage 
of this content within an existing formal and semantically interoperable resource. Such 
representation fills a critical gap for developing applications which safeguard biospecimen 
resources and enable querying based on their permissions for access and use. By modeling 
information regarding permissions in an ontology, the tremendous heterogeneity of these 
permissions at a range of levels (e.g., federal regulations, norms, patients’ consent documents) 
can be richly represented using entity-relationship links and embedded rules of inference and 
inheritance. Furthermore, by developing this content in the Informed Consent Ontology, missing 
content will be added to the Open Biological and Biomedical Ontology (OBO) Foundry, a Basic 
Formal Ontology-based biobanking suite of ontologies, enabling use alongside other widely-
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adopted biomedical ontologies (e.g., Data Use Ontology, Information Artifacts Ontology) and 
serves as a valuable contribution for biobank specimen and information management.
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Chapter 2 Exploring Regulations and Norms That Bear Authority Over or 
Guide Reuse of Residual Clinical Biospecimens and Health Data in the 
United States 
 
1. Introduction  
When patients seek health care services, portions of their blood, body fluid, or tissues 
may be removed for diagnostic or therapeutic purposes. Portions of these specimens often remain 
after their clinical indication is fulfilled. These portions, hereafter referred to as residual clinical 
biospecimens, are either discarded or sent to a biorepository.[22] Besides their abundance and 
relative representativeness of the healthcare-accessing and -seeking population, residual clinical 
biospecimens are desirable for their quality; they are processed and stored according to stringent 
standards and analyzed within CLIA-certified labs.[23] Residual clinical biospecimens are also 
linked or linkable to patients’ electronic health records, which are cornucopias of information. 
These features make residual clinical biospecimens particularly valuable to researchers. 
Furthermore, developing biospecimen collections through direct-to-biobank donation or research 
participation is resource intensive and faces challenges for participant recruitment. In response to 
such challenges, biobanks and researchers often turn to “real world” collections of residual 
clinical biospecimens.[22] 
The United States of America (US) has clearly defined requirements for human subjects’ 
research, which includes reuse of biospecimens collected during research procedures. In addition 
to analysis in the primary study, investigators may request consent for reuse of biospecimens for 
broad categories of future research studies, unforeseen at the time of recruitment.[24,25] 
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However, reuse of residual clinical biospecimens is governed by multiple regulations. Because of 
the multiple sources of authority over reuse of residual clinical biospecimens, navigating the 
complex ecosystem of permissions to reuse clinical biospecimens is challenging for 
biorepositories and those who wish to identify biospecimens that are stored across 
biorepositories. Our long-term goal is to develop a computable semantic model, or ontology, 
which can be referenced for a variety of applications, including for example software 
applications that assist in identifying and making decisions about the permitted reuse of residual 
specimens and text-based identification of permissions within consent documents.  
The purposes of this scoping review were threefold. First, we aimed to identify relevant 
federal regulations and norms (e.g., best practices, guidance documents) that bear authority or 
give guidance over reuse of residual clinical biospecimens and health data in the US. Second, we 
aimed to gather domain experts’ interpretations of the permissions by which such reuse may 
occur. Third, we aimed to gather domain experts’ interpretations of the key issues and concepts – 
including the overlap, congruency, and gaps – that must be considered when interpreting these 
regulations and norms. The assumption is that the literature serves as a vetted, peer-reviewed 
source of domain experts’ interpretations. We fully recognize and appreciate the importance of 
the ethical considerations around the issues of reusing residual clinical biospecimens and health 
data, but this paper does not directly address ethics. Rather, we solely focus on the authority and 
guidance that the identified regulations and norms bear on such reuse.  
2. Methods 
 2.1. Design 
We conducted a scoping review to identify sources of regulation or guidance that bear 
authority on reuse of residual clinical biospecimens and health data. Scoping reviews enable 
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exploration and synthesis of a breadth of knowledge through mapping key information or 
evidence. Their design is well-suited to examining fields that are complex, are emerging or 
developing, or have not yet been comprehensively reviewed.[26,27]  
 2.2. Search Strategy 
To obtain a broad perspective of permissions for residual clinical biospecimen and health 
data reuse, a variety of biomedical, legal, health ethics and policy databases were searched, 
including: PubMed, HeinOnline, NexisUni, Health Policy Reference Center, Philosopher’s 
Index, and Public Affairs Index. Selection of these databases and queries for each database were 
advised and reviewed by a law librarian and a health informationist. The base set of search terms 
included synonyms for specimens, sharing, and consent or permission. However, use of these 
terms in HeinOnline yielded surfeit and extraneous results (n= 3378) that were unrelated to our 
topic of interest. Under the guidance of the law librarian, we added names of known federal 
regulations that have influence on biospecimen use to the search terms. Likewise, due to the 
scarcity of results in Health Policy Reference Center (n= 31), Philosopher’s Index (n= 4), and 
Public Affairs Index (n= 4), the search was broadened by only using the specimen and 
consent/permission terms (see table A1 for a complete list of search terms for each database). 
Filters were set to include only reports written in English and published after 1996 (i.e., the year 
Health Insurance Portability and Accountability Act (HIPAA) was enacted). Filters were set in 
HeinOnline and NexisUni to only include law reviews and journal articles written on policies 
within USA jurisdiction. All searches were finalized on May 14, 2019.  
 2.3. Screening 
All retrieved records were imported to a citation management software, and duplicates 
were removed. Two reviewers, both trained as clinical research scientists, independently 
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screened titles and abstracts followed by full-text manuscripts. They met three times for each of 
the screening stages to discuss challenges and uncertainties in study selection and to refine the 
inclusion and exclusion criteria. In scoping reviews, methods allow for inclusion and exclusion 
criteria to evolve as retrieved manuscripts are explored.[27] The final inclusion criteria 
incorporated manuscripts that discussed the conditions by which residual clinical biospecimens 
and their data could be shared or reused. Figure 1 depicts the entirety of the screening pipeline, 
from manuscript retrieval to final inclusion, as well as exclusion criteria. 
 2.4. Management and Extraction 
Information was extracted from the manuscripts and organized in spreadsheets. Each row 
included citation information, the authors’ stated purpose of the manuscript, key concepts used to 
frame discussions of residual clinical biospecimen and health data reuse, and the key issues or 
assertions made by the authors. For each regulation or norm relevant to residual clinical 
biospecimen and health data reuse in the US discussed in these manuscripts, a sub record was 
created that included its name, date passed (and dates of significant revision), purpose or aim, 
topics used by the authors to frame discussions of that document, all conditions by which 
residual clinical (or all) biospecimens can be shared or reused, and the authors’ evaluation of the 
regulation or norm. 
3. Results 
The final database search yielded 842 unique records after duplicates were removed. 
Titles and abstracts were screened and included if they discussed specimens collected during 
clinical procedures or biospecimens generally, regulations or norms applicable in the US, and 
any term related to sharing or reuse. Of note, much of the legal literature did not include 
abstracts, which explains the high number of manuscripts that qualified for full-text review but 
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were subsequently excluded. Two hundred fifty-four full-text manuscripts were further screened 
for inclusion. Twenty-five manuscripts were included in the final review.   
 12 
Figure 1. PRISMA Flow Diagram for Identifying Regulations or Norms that Bear Authority on Reuse of Residual Clinical 
Biospecimens and Health Data in the US. 
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 3.1. Identified Regulations and Norms 
From the included manuscripts, we identified eleven regulations and fifteen norms (n=26) 
that bear authority over or guide reuse of residual clinical biospecimens and health data in the 
United States (Table 1 presents all identified regulations and norms identified in this review). 
Only one manuscript specifically examined conditions for reuse of residual clinical 
biospecimens, and its analysis only included HIPAA and reuse in research.[28] While there was 
little explicit focus on residual clinical biospecimens across the literature, regulations, and 
norms, these documents did often target concepts (e.g., genetic information, personally 
identifiable health information, all human biospecimens) that overlapped with and motivated our 
interests with reuse of residual clinical biospecimens. Identified norms came from both national 
and international sources, largely professional and nonprofit organizations and multinational 
consortiums with US participation. 
 3.2. Permissions for Reuse of Residual Clinical Biospecimens 
Identified permissions for reusing residual clinical biospecimens and health data varied 
widely across the regulations and norms. With an eye towards thematic analysis methods, we 
identified several themes of permissions across the regulations and norms (see Table 1): 
 3.2.1. Permissions Conditional on Consent or Authorization.  
Half of the identified regulations and norms (n= 13) emphasized the importance of 
consent or authorization when reusing residual clinical biospecimens and health data for non-
clinical purposes. HIPAA and the 21st Century Cures Act permits these biospecimens and health 
data to be used for future research so long as patient authorization is obtained.[28,29] Likewise, 
the American Medical Association (AMA) and International Society for Biological and 
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Environmental Repositories (ISBER) echo these sentiments; they specify that clinicians should 
obtain consent from patients
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Table 1. Federal Regulations and Norms that Bear Authority on Reuse of Residual Clinical Biospecimens and Heath Data 
 Regulation/Norm 
(Key Dates) 
Purpose of the 
Regulation/ Norm 
Interpretations of Permissions for Reusing Residual Clinical Biospecimens and Health 
Data from the Literature 
Federal Regulations 
21st Century Cures 
Act 
(2016)  
To modernize and 
expediate the research and 
approval process of the 
FDA for drugs and 
medical devices.[29] 
The following enact changes to the HIPAA Privacy Rule:  
• PHI disclosure between covered entities is exempt if for healthcare operations or data aggregation.[29] 
• Sharing PHI for quality, safety, or effectiveness research of FDA-regulated products is exempt as a 
“public health activity,” even if shared with drug companies and commercial entities.[29] 
• Authorizations for future research are allowable if the purpose of the research, dates for authorization, 
and statement that authorization will remain in effect unless revoked are clearly stated.[29] 
Affordable Care Act 
(ACA)  
(2010; 2014 revised) 
To extend health coverage 
to uninsured 
Americans.[30] 
• Genetic information cannot be used by health insurers to determine pre-existing conditions, eligibility, 
or rates on premiums.[30,31] 
 
Americans with 
Disabilities Act 
(ADA)  
(1990; 2008 revised) 
To protect the civil rights 
of persons with 
disabilities.[32] 
• Employers, employment agencies, labor organizations, joint labor management committees, and public 
services cannot use genetic information to discriminate based on disability.[30,32] 
Clinical Laboratory 
Improvement Act 
(CLIA) 
(1988) 
To regulate labs that test 
for diagnosis, prevention, 
treatment, or assessment 
of human beings.[33] 
• Labs must ensure patients’ confidentiality when specimens are under the labs’ control.[33] 
• Test results may only be released to authorized persons or the initiator of the request.[33] 
Common Rule  
(1991; 2018 revised) 
To protect participants 
from the risks involved in 
research.[34] 
• Researchers can use residual clinical biospecimens and health data without patients’ consent: 
o If an IRB determines that the data are deidentified.[33,35–39] 
o If an IRB grants a consent waiver.[33,35,36]  
o If the data is publicly available.[33] 
• Investigators must get IRB approval and consent when prospectively intending to use residual clinical 
biospecimens (or collect extra material) and health data for a specific research study.[35–37] 
Food and Drug 
Administration 
Amendments Act 
(FDAAA)  
(2007) 
To regulate research for 
drugs or medical devices 
with human subjects, 
including use of 
biospecimens and health 
data.[33,40]  
 
• Biobanks and investigators that are engaged in research with specimens used to investigate drugs or 
medical devices must be subject to FDA Human Subjects protections, unless: 
o An exception is met.[33] 
o An IRB deems that a biospecimen is not individually identifiable.[33] 
• The FDA may retrospectively retrieve entire medical records or previously stored biospecimens during 
surveillance studies without individuals’ consent or authorization.[40] 
o However, if new specimens or data are needed prospectively, the FDA must obtain consent.[40] 
Genetic Information 
Nondiscrimination 
Act (GINA) 
(2008) 
To protect from genetic 
discrimination by insurers 
& employers.[41]  
NOTE: Enactment of GINA modified HIPAA, explicitly designating genetic information as PHI.[30] 
• Health insurers cannot request, require, or use genetic information to make any underwriting decisions, 
including determining coverage, eligibility, or premiums.[31–33,41,42] 
• Employers must not make employment-related decisions based on genetic information.[31,33,41,42] 
 16 
 Regulation/Norm 
(Key Dates) 
Purpose of the 
Regulation/ Norm 
Interpretations of Permissions for Reusing Residual Clinical Biospecimens and Health 
Data from the Literature 
Health Insurance 
and Portability and 
Accountability Act 
(HIPAA)  
(1996; 2003 revised; 
2013 revised) 
To adopt national 
standards for electronic 
health information 
exchange.[28] 
  
The Privacy Rule: To 
protect uses and 
disclosures of individually 
identifiable health 
information.[38] 
• Covered entities must obtain patients’ authorization to disclose PHI, including biospecimens, unless 
otherwise permitted.[28,30,33,42–44] Authorization must include:  
1. Description of PHI to be used or disclosed 
2. Who is authorized to disclose the PHI 
3. Who will receive or use the PHI 
4. Description of purpose of use or disclosure 
5. Expiration date or event 
6. Statement of right to revoke authorization 
7. Statement of exceptions for right to revoke 
8. Statement that the covered entity may not 
“condition treatment, payment, enrollment, or 
eligibility on the authorization” 
9. Statement that further disclosure of the PHI by 
the recipients may no longer be protected  
10. Patients’ signatures and dates of signature [28] 
• When authorization cannot be obtained,  
o Covered entities may share patient information, including biospecimens, when identifiers are 
removed or an expert determines the risk of reidentification is very small.[39,41,45] 
o An IRB issues a waiver of authorization [28,43] for accessing PHI to perform eligibility screening 
for recruitment, or when PHI is about deceased individuals.[28,33] 
• PHI, including biospecimens, can be disclosed for treatment, payment, health care operations; about 
victims of abuse, neglect; for judicial, administrative, law enforcement; disclosures about decedents or 
for cadaveric tissue donation; averting serious threats to self or others; if required by law; for 
specialized government functions; for public health surveillance; and workers’ 
compensation.[29,30,33,42,43] 
• Limited data sets may be released when recipients sign data use agreements.[28,33,39,41,43] 
• Recipients of limited data sets must require “any agents to whom it provides the limited data set agree 
to the same restrictions and conditions that apply to the limited data set recipient.”[33]  
• Covered entities may sell PHI for research and when remuneration is limited to the cost of preparation 
and transmission.[33] 
• Health insurers cannot use genetic information to determine preexisting conditions, eligibility, or 
premiums.[30,44] 
Newborn Screen 
Saves Lives 
Reauthorization Act 
(2014) 
To provide federal funding 
for education programs 
and recommendations for 
newborn screening.[46] 
• Research on newborn dried blood spots is human subjects research which means consent and IRB 
oversight must be obtained.[33] 
Rehabilitation Act 
(1973) 
To prevent discrimination 
based on disability.[32] 
• Federal agencies, employers with >$2500 federal contracts, or any federally-funded program or activity 
cannot discriminate based on disability, including inferences made based on genetic information.[32] 
42 U.S. Code § 241. 
Research and 
Investigations 
Generally  
(2011) 
To protect the privacy of 
research participants. 
 
• Researchers collecting sensitive and identifying data can request a certificate of confidentiality (which 
authorizes researchers to avoid compelled disclosure) from DHHS.[31] 
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 Regulation/Norm 
(Key Dates) 
Purpose of the 
Regulation/ Norm 
Interpretations of Permissions for Reusing Residual Clinical Biospecimens and Health 
Data from the Literature 
Norms (e.g., Best Practices, Guidance Documents) 
AMA: Commercial 
Use of Human 
Tissues 
(2008) 
To provide guidance on 
physicians using patients' 
biospecimens for 
commercial purposes.[47] 
• Physicians should obtain consent from patients in order to use their tissues in research.[47] 
• Biospecimens should not be used for commercial purposes without patients’ informed consent.[47] 
• If patients’ biospecimens are used commercially, profit-sharing between patient and doctor should be 
facilitated under lawful contract.[47] 
CIOMS: 
International 
Ethical Guidelines 
for Epidemiological 
Studies 
(1982; 1991 revised; 
2009 revised) 
To provide guidelines to 
indicate ethical principles 
when conducting 
epidemiological 
research.[48] 
Secondary use of identifiable medical records and biospecimens is allowable when all the following 
requirements are achieved: 
• Ethics committee concludes the research is “minimal risk,”  
• The rights of patients will not be violated, 
• Privacy and anonymity are assured, 
• The research is designed to answer an important question, or  
• Consent is impracticable.[49] 
GA4GH: 
Framework for 
Responsible Sharing 
of Genomic and 
Health-Related Data 
(2014) 
To provide a framework 
for harmonized and 
interoperable sharing of 
genomic and health related 
data.[49,50] 
• Secondary use of biospecimens and data may occur when the uses are consented for or approved.[49] 
• When consent to data sharing has been obtained, the rights of citizens to benefit from the advances in 
medicine and of scientists to be recognized for their contribution should be recognized.[51] 
• Privacy and security safeguards should be proportionate to the real risks of data breaches.[51] 
HUGO: Bioethics 
Committee 
1995 
To advocate for privacy 
protections in the context 
of genomics.[49] 
• Secondary use of biospecimens may occur if general notification is provided, the participant does not 
object, and the sample is coded or anonymized.[49] 
International 
Declaration on 
Human Genetic 
Data (IDHGD)  
(2003) 
To protect confidentiality 
of medical data, including 
genetic and proteomic.[49] 
• Secondary use of biospecimens and data are allowable when the analysis is in the public interest or 
when "irretrievably linked."[49] 
ISBER: Best 
Practices for 
Repositories 
2012 (revised) 
To guide standardizing 
methods for collection, 
long-term storage, 
retrieval, and distribution 
of biospecimens to enable 
their future use.[52] 
• If biospecimens are still necessary for clinical care, they must not be used for research. [52]  
• “Specimens and/or data should only be made available for ethical and scientifically appropriate 
research that is expected to contribute to scientific discovery.”[52] 
• Donor consent (specific or broad) should be obtained unless waived by an ethics committee.[52] 
• Biorepositories should protect donor confidentiality and ensure that specimens and associated data are 
only shared according to the authorization/consent and privacy standards they were obtained under.[52] 
• Biospecimens and associated data should be deidentified prior to release, unless identifiers are 
absolutely necessary and an IRB approves transmission of identifiers.[52] 
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 Regulation/Norm 
(Key Dates) 
Purpose of the 
Regulation/ Norm 
Interpretations of Permissions for Reusing Residual Clinical Biospecimens and Health 
Data from the Literature 
OECD: Guidelines 
on Human Biobanks 
and Genetic 
Research Databases 
(2009) 
To guide management of 
Human Biobanks and 
Genetic Research 
Databases (HBGRD).[53] 
• The operators of the HBGRD should strive to make data and materials rapidly and widely available to 
researchers to advance knowledge and understanding.[50] 
• Secondary use of biospecimens and genetic data can only occur following ethics board approval.[49] 
EEOC: Policy 
Guidelines  
(1995) 
To protect applicants and 
employees from 
discrimination.[54] 
• Genetic information cannot be used to discriminate for employment opportunities.[32] 
UNESCO: 
International 
Declaration on 
Human Genetic 
Data (2003) 
To address ethical issues 
related to medicine, life 
sciences and associated 
technologies.[55] 
• "Researchers should… encourage the free circulation of human genetic data and human proteomic data 
in order to foster the sharing of scientific knowledge."[50] 
UNESCO: Universal 
Declaration on 
Bioethics and 
Human Rights 
(2005) 
To address ethical issues 
related to medicine, life 
sciences and associated 
technologies.[55] 
• "Benefits resulting from any scientific research and its applications should be shared with society as a 
whole and within the international community, in particular with developing countries.”[50] 
• “States should foster international dissemination of scientific information and encourage the free flow 
and sharing of scientific and technological knowledge."[50] 
UNESCO: Universal 
Declaration on the 
Human Genome 
and Human Rights 
(1997) 
To provide ethical 
standards for human 
genetic research.[56] 
• "States should make every effort… to continue fostering the international dissemination of scientific 
knowledge concerning the human genome, human diversity, and genetic research and, in that regard, to 
foster scientific and cultural co-operation, particularly between industrialized and developing 
countries."[50] 
UNESCO: Report of 
the International 
Bioethics Committee 
on Consent (2008) 
To guide obtaining 
informed consent for 
clinical and research 
purposes.[57] 
• Secondary use of clinical biospecimens and health data is only allowed when an expert deems that re-
consent is impracticable.[49] 
• Participants must have a right to withdraw their specimens.[49] 
WMA: Declaration 
of Helsinki 
(1964; 2008 revised) 
To outline physicians’ 
duties in research.[51] 
• Physicians may pursue secondary use on "identifiable human material or data" for research without 
consent only when re-consent is impossible or impracticable, and only with ethics review committee 
approval.[49] 
WMA: Declaration 
of Taipei 
(2002; 2016 revised) 
To guide ethical storage 
and use of identifiable data 
and biospecimens.[58] 
• Biobanks' and health databases' requirements for informed consent for using identifiable biospecimens 
may be waived, only when there is a “clearly identified, serious, and immediate threat where 
anonymous data will not suffice.”[38] 
Key: AMA: American Medical Association; CIOMS: Council for International Organizations of Medical Sciences; EEOC: Equal Employment Opportunities 
Commission; GA4GH: Global Alliance for Genomics and Health; HUGO: Human Genome Organization; IDHGD: International Declaration on Human 
Genetic Data; ISBER: International Society for Biological and Environmental Repositories; NCI: National Cancer Institute; OECD: Organization for 
Economic Cooperation and Development; UNESCO: United Nations Educational, Scientific, and Cultural Organization; WMA: World Medical Association 
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in order to use their biospecimens in research, and that all future uses must correspond to the 
conditions specified in the consent.[47,52]  
However, there are multiple permissible options for those who wish to reuse residual 
clinical biospecimens without obtaining authorization or consent. As an example, the Common 
Rule (CR), Food and Drug Administration Amendments Act (FDAAA), HIPAA, ISBER, and 
United Nations Educational Scientific and Cultural Organization (UNESCO) permit reuse of 
residual clinical biospecimens and health data when (a) an Ethics Committee approves the 
intended uses, (b) an ethics committee waives the authority of another regulation, or (c) the 
biospecimens and data are appropriately deidentified.[28,33,49,52] Of note, the Council for 
International Organizations of Medical Sciences (CIOMS), UNESCO, and World Medical 
Association (WMA) state that such options should only be used when consent is not possible or 
is “impracticable.”[38,48,49] It is also interesting to note that research on newborn dried blood 
spots is not eligible for such exceptions, and consent and IRB approval must be obtained for this 
type of residual clinical biospecimens under the Newborn Screen Saves Lives Reauthorization 
Act.[33] 
 3.2.2. Permissions Conditional on Identifiability. Identifiability plays a pivotal 
role in reuse of residual clinical biospecimens and health data. The nature of if and how 
identifiable these resources determines which regulations or norms apply to their reuse. As an 
example, permission to use deidentified residual clinical biospecimens and health data for 
research is exempt from regulation under the US Common Rule and FDAAA, as research using 
deidentified resources is not considered human subjects research.[33,34] HIPAA similarly 
applies only to protected health information, i.e., that which is individually identifiable.[41] 
Rothstein points out that US federal regulations demonstrate a bimodal perspective of 
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identifiability; residual clinical biospecimens and health data are either identifiable and all of the 
aforementioned regulations apply, or are not identifiable and therefore are completely 
unprotected.[39] Multiple norms emphasize the importance of deidentification, including the 
International Declaration on Human Genetic Data (IDHGD), which permits biospecimen reuse 
when they are “irretrievably linked” to identifying information.[49] 
 3.2.3. Permissions Conditional based on Specified Uses. While some 
permissions within regulations and norms are specific to the context of specimens’ and data’s 
collection (i.e., whether they were collected during clinical or research procedures), many others 
instead focused on the downstream uses of all biospecimens or health data. Such downstream 
uses include use for discrimination, conditions for commercialization, and promoting public or 
individual benefit for specimen contributors. There was consensus among authors of the included 
manuscripts that it was never permissible, citing multiple regulations and norms, to use genetic 
information – regardless of context of collection – to make employment- or insurance-related 
decisions. These regulations and norms include the Affordable Care Act (ACA), Americans with 
Disabilities Act (ADA), Genetic Information Nondiscrimination Act (GINA), HIPAA, 
Rehabilitation Act, and the Equal Employment Opportunities Commission’s (EEOC) Policy 
Guidelines.[30–33,41,42,44] 
Permissions for commercialization of biospecimen and health data are considerably more 
varied across regulations and norms. The AMA specifies that physicians are never permitted to 
release or use their patients’ biospecimens for commercial purposes without their consent.[47] 
However, the 21st Century Cures Act takes a much different stance, that protected health 
information (PHI; including biospecimens) may be shared with commercial entities for 
examining the quality, safety, or effectiveness of FDA-regulated products without adhering to 
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HIPAA’s authorization requirements.[29] HIPAA further permits covered entities to sell PHI for 
research and when there is remuneration, renumeration must be limited to the cost of preparation 
and transmission.[33] 
Lastly, whether using patients’ biospecimens and health data for commercial transactions 
or not-for-profit research, there was consensus across norms that benefit should extend beyond 
the investigators. UNESCO’s International Declaration on Human Genetic Data, Universal 
Declaration on Bioethics and Human Rights, and Universal Declaration on the Human Genome 
and Human Rights specify that investigators should freely and widely share biospecimen 
resources, scientific knowledge, and benefits from discovery, particularly between industrialized 
and developing countries.[50] The Organisation for Economic Co-operation and Development 
(OECD) likewise prescribes that biospecimens and health data be made widely available to 
advance scientific inquiry and discovery; however, IDHGD and ISBER only permit such use 
when the research is expected to contribute to ethical and scientifically appropriate research or is 
in the public’s interest.[49,52] 
 3.3. Key Issues. 
The authors of the identified manuscripts widely agreed that the most prevalent issue 
related to reuse of residual clinical biospecimens and health data is that such reuse remains 
largely unregulated, or the regulations are disjointed and difficult to interpret, across national and 
international contexts.[30,32,33,41,43,50,52] Harrell and Rothstein argue that, “when viewed in 
the context of international biobanking it frequently becomes difficult to conclude with any 
certainty whether international sharing of specimens and health data is lawful."[33] HIPAA and 
the Common Rule are designed to protect individuals privacy and risk from harm. However, the 
alternatives to consent provided in these regulations may be more expedient and less 
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administratively burdensome than tracing consent permissions. As such, “the benefits of 
[HIPAA’s] Privacy Rule [are] no longer be commensurate with its costs in terms of aggravation, 
expense, and widespread misunderstandings and misapplications"[33] and “researchers have 
little reason to avail themselves of the new broad consent option.”[35] 
Other major issues when sharing or reusing residual clinical biospecimens and health data 
include lack of consensus surrounding prioritization of individual’s rights to privacy, 
confidentiality, and autonomy over materials that were once part of them or information about 
them, or the public benefit that may be derived from having the most resources possible to 
advance scientific discovery. These tensions are exemplified by Dove, who stated, “Unduly 
restricting data sharing across national borders or the matching of biospecimens with health 
registries and patient records limits the possibility of validating biological findings in larger 
cohorts… But sharing personally identifiable individual and familial data requires [consideration 
of] ethical and legal interests.”[50] Major issues and key concepts identified in the literature are 
presented in Table 2. 
4. Discussion 
We identified a set of twenty-six regulations and norms that apply to reuse of residual 
clinical biospecimens and health data in the US through this scoping review. We further 
identified and described the permissions in these regulations and norms that condition how and 
when residual clinical biospecimens and health data can be reused, and the major issues when 
examining these conditions. Inconsistencies in permissions coalesce in a patchwork of rules that 
make it difficult to tell which regulations or norms apply to a given use, or if the applicable 
regulations or norms even agree with each other.[59] We are not aware of other reviews that
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Table 2. Major Issues and Key Concepts in the Literature for Reuse of Residual Clinical Biospecimens and Heath Data 
Citation Purpose of Manuscript Major Issues Key Concepts  
Ahn, 2015 
[41] 
To advocate for a balance between 
privacy rights and availability of genomic 
information for research 
Genomic data may be linked to other publicly available 
information. The implications of genomic info are unknown, and 
balancing data availability and privacy has yet to be regulated. 
• Identifiability 
• Discrimination 
• Privacy 
Beskow, 
2016 [37] 
To reflect how public opinion should 
affect biospecimen research policy. 
Public input on approaches for shared interests should inform 
biospecimen research policies. Consent approaches should reflect 
realistic aspirations and highlight specimen contributors’ 
autonomy. 
• Consent 
• Confidentiality 
• Trust 
• Autonomy 
Bierer, 
Barnes, & 
Lynch, 2017 
[34] 
To highlight revisions to the Common 
Rule and their implications for research 
participants. 
The new provisions will likely be “interpreted and implemented in 
ways that will insulate the regulated community from compliance 
enforcement… the crucial challenge will be to continue upholding 
their commitment to improving human health and benefiting the 
public, while appropriately protecting research participants.” 
• Human Subjects 
Protections 
• Benefit Sharing 
Bledsoe, 
2017 [38] 
To review policy developments around 
evolving ethical issues for biobanking 
and provide perspectives on future issues. 
Biobanking has experienced dramatic changes in the research 
environment, regulations and policies, and evolving ethical issues. 
As technologies evolve, these issues should continue to be debated. 
• Identifiability  
• Transparency 
• Accountability 
Bregman-
Eschet, 2012 
[60] 
To examine how regulations of genetic 
information should consider privacy and 
autonomy of individuals. 
Genetic databases, despite their highly sensitive nature, are largely 
unregulated in the United States. 
• Privacy 
• Autonomy 
• Property rights 
Campbell et 
al., 2012 [52] 
To provide guidance on the 
standardization of methods for collection, 
long-term storage, retrieval, and 
distribution of specimens that will enable 
their future use. 
Biorepositories are the intermediary between biospecimen 
contributors and those who wish to use biospecimens. Biospecimen 
resources are “currently regulated by an amalgam of differing and 
occasionally conflicting laws and policies.” Repositories must 
consider discrepant sources of authority when sharing samples and 
data across geographic borders and jurisdictions.  
• Human Subjects 
Protections 
• Privacy & Confidentiality 
• Identifiability 
• Consent 
• Benefit Sharing 
Dove, 2015 
[50] 
To describe international regulation of 
biobanks’ privacy protections, areas of 
consideration for such regulations, and 
the need for harmonizing regulations 
within a global framework. 
“Unduly restricting data sharing across national borders or the 
matching of biospecimens with medical registries and patient 
records limits the possibility of validating biological findings in 
larger cohorts… But sharing personally identifiable individual and 
familial data requires [consideration of] ethical and legal interests.” 
• Promote Sharing 
• Privacy & Confidentiality 
• Identifiability  
• Consent 
 
Edwards, 
2008 [47] 
To argue that United States' regulations 
do not adequately balance promotion of 
future research and patients’ autonomy 
over their biospecimens. 
Many patients are unaware that blood or tissue collected from their 
bodies during clinical care are not thrown out but rather saved. 
Although hospitals require patients to sign consent forms, these 
forms are heterogeneous and largely unregulated. “Thus, patients 
are generally left with little, if any, information about how their 
samples will be used or who might be using them.” 
• Scientific Benefit 
• Autonomy and Rights  
• Ownership 
• Informed consent 
• The right to withdraw 
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Citation Purpose of Manuscript Major Issues Key Concepts  
Evans, 2009 
[40] 
To review regulations for drug 
development, including analysis of 
medical records and “previously stored 
tissue specimens.”  
FDAAA allows analysis of health records and residual clinical 
biospecimens for post-market research. However, it defers to 
voluntary arrangements to collect such information, which may 
create barriers that impede discovery. 
• Scientific Benefit vs. 
Individual Harms 
Harrell & 
Rothstein, 
2016 [33] 
To review regulations of biobanking 
research and privacy laws in the US and 
global biobank research. 
"American biobanking laws and practices are diffuse, disjointed, 
and largely indecipherable… When viewed in the context of 
international biobanking it frequently becomes difficult to conclude 
with any certainty whether international sharing of specimens and 
health information is lawful." 
• Privacy & Confidentiality 
• Informed Consent 
• Security 
Hsu, 2010 
[30] 
To examine US regulations that address 
privacy and discrimination concerns 
related to genetic information. 
“Current legislation [does not balance] competing interests of 
privacy and discrimination… The legal framework of genetic 
privacy and nondiscrimination remains muddled.”  
• Privacy 
• Discrimination 
Hudson, 
2011 [31] 
To describe evolving policies pertinent to 
genetic and genomic research, the 
integration of genetics into clinical care, 
and issues raised by genetic technologies. 
“First, research using collections of biologic specimens, genomic 
data, and information from medical records has amplified the long-
standing yet unresolved issue about consent for future research that 
is unanticipated at the time of specimen collection. Second, the 
push for broad access to research data sets has raised privacy 
concerns. Third, as researchers seek to share data with colleagues, 
the issue of whether and how to share research results with study 
participants remains vexing, particularly in the absence of explicit 
prior consent from participants." 
• Scientific Benefit 
• Patients and Human 
Subjects Protections 
• Consent 
• Confidentiality 
• Return of Research 
Results 
Ireni-Saban, 
2014 [32] 
To compare genetic information policies 
in the US and UK for privacy, non-
discrimination, and benefit sharing. 
"Governing genetic data across countries reveals an ongoing 
absence and inconsistency at the level of regulatory systems." 
• Privacy 
• Discrimination 
• Benefit Sharing 
Lynch, 2017 
[36] 
To evaluate the Common Rule's options 
for obtaining consent. 
The Common Rule’s deidentification or broad consent 
requirements lack transparency, but societal benefits outweigh 
personal autonomy risks.  
• Consent Models 
Lynch & 
Meyer, 2017 
[35] 
To describe the shortcomings of the 
revised Common Rule, particularly those 
related to broad consent. 
Considering the burden of tracking conditions specified when using 
broad consent, “researchers have little reason to avail themselves of 
the new broad consent option.” Additionally, it remains unclear if 
biospecimens ought to be treated as inherently identifiable. 
• Burden of tracking 
consent specifications  
• Autonomy 
• Identifiability 
Maschke, 
2005 [43] 
To describe the myriad of biobanking 
regulations internationally and present 
relevant ethical issues.  
"No binding international regulatory framework addresses [use of 
biospecimens]. Instead, a patchwork of national laws, regulations 
and ethics advisory body guidelines govern the collection, storage 
and research use of biological samples." 
• Consent 
• Commercialization  
• Public Benefit 
• Property Rights 
Rosati, 2005 
[28] 
To discuss how the HIPAA Privacy Rule 
allows release of biospecimens and 
protected health information for research. 
The Privacy Rule’s requirements for the release of biospecimens 
and protected health information is complicated and a source of 
confusion for covered entities and researchers alike. 
• Identifiability 
• Consent vs. Authorization 
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Citation Purpose of Manuscript Major Issues Key Concepts  
Rothstein, 
2010 [39] 
To consider the effect of using 
deidentified biospecimens and health 
information in research without the 
knowledge, consent, or authorization of 
the individual on privacy. 
In addition to current strategies for deidentifying health records and 
biological specimens being insufficient to protect privacy and 
respect autonomy in research, “the deidentification regulations of 
the Common Rule and the Privacy Rule are inexplicably and 
unjustifiably inconsistent.”  
• Privacy 
• Identifiability 
• Autonomy 
• Trust 
• Commercial Exploitation 
Rothstein, 
2016 [29] 
To describe how the 21st Century Cures 
Act and Common Rule revisions weaken 
HIPAA’s privacy protection. 
 “The benefits of the Privacy Rule will no longer be commensurate 
with its costs in terms of aggravation, expense, and widespread 
misunderstandings and misapplications."  
• Identifiability 
Rothstein, 
Knoppers, & 
Harrell, 2016 
[51] 
To highlight ethical issues, regulation, 
and guidance of international biobanking, 
and focus on the range of laws, policies, 
and practices for biobanking and privacy 
protections in the US. 
Agreements, guidelines, contracts, memoranda of understanding, 
and polices create up a complex context for international 
biobanking. The US lacks regulations that specifically address 
biobank research. Development and harmonization of biobanking 
regulations is needed. 
• Privacy & Security 
• Consent 
• Identifiability  
Shayeb, 
2017 [61] 
To argue that individuals have property 
rights over their genetic information. 
US regulations do not protect genetic information as the property 
of individuals. "The question of whether there should also be a 
universally recognized property interest in genes remains wide 
open for further discussion." 
• Property Rights  
• Consent 
• Autonomy 
• Privacy 
Shea, 2003 
[44] 
To review and evaluate the development 
of HIPAA, including the intersection of 
the Privacy Rule and genetic information. 
While deidentification must occur for health information to be used 
for secondary purposes, it is unclear if genetic information is 
always protected under the Privacy Rule.  
• Privacy 
• Security 
• Authorization vs. consent 
Spector-
Bagdady et 
al., 2019 [62] 
To describe considerations for cell line 
research following revisions to the 
Common Rule and offer 
recommendations for regulation of 
biospecimen research. 
Considering risk of reidentification is significantly lower using cell 
lines compared to other types of biospecimens, “lack of nuance in 
defining… specific classes of biospecimens [in regulations] may 
unintentionally impede the rate of research progress and drive up 
costs associated with specific biospecimens.” 
• Public benefit 
• Identifiability  
• Property Rights 
• Autonomy  
• Privacy 
Thorogood 
& Zawati, 
2015 [49] 
To review international privacy norms 
governing human biobanks and genomic 
databases. 
Biobanking is guided by a range of overlapping national and 
International norms, sometimes generated without consideration of 
biobanks directly. Approaches to privacy differ across cultures and 
legal traditions. 
• Privacy 
• Consent 
• Identifiability 
• Access 
• Security 
Wolf, 2017 
[42] 
To explain risks and protections for 
participants in genomic research. 
US regulations largely require authorization to disclose genomic 
and health information, but there are multiple exceptions. Patients 
may not realize and may object to how their information is being 
used without their consent.  
• Consent 
• Confidentiality 
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 specifically examine the multiple sources of authority and guidance around permissions to reuse 
patients’ biospecimens and health data. 
The requirement to obtain consent or authorization from specimen contributors, both 
patients and research subjects alike, is widely inconsistent across regulations and norms. 
Whereas the Common Rule provides rigorous consent and ethics review board requirements for 
prospective human subjects’ research, HIPAA authorization forms may contain much less 
information and do not require oversight from an ethics review board. Likewise, recent 
discussions surrounding the Common Rule revisions revealed consensus that blanket consent 
(i.e., permits any and all future uses) is unethical as it cannot yield truly informed consent.[63] 
However, HIPAA authorization requirements allow for almost universal reuse of protected 
health information, including biospecimens, so long as a statement is “briefly disclosed in a 
general consent-to-treat form.”[37] In other words, authorization for reuse of residual clinical 
biospecimens and health data may be lumped into consent forms for health care services, and 
may not necessarily allow for opting out of some permissions named in the form. There is an 
argument that it is unreasonable to assume that patients automatically agree to contribute their 
personal bodily materials and health records for secondary purposes, when they seek health care 
services.[29] Even if such blanket consent requirements and lack of ethics review board 
oversight is deemed acceptable, regulations for reuse of residual clinical biospecimens in 
research differ based on the type of biospecimen. For example, the Newborn Screens Saves Lives 
Act explicitly classifies research using newborn dried blood spots, collected from babies’ heels 
shortly after birth, as human subjects research.[33] Therefore any research using these newborn 
blood spots requires Common Rule-compliant consent processes at the time of collection and 
ethics review board oversight. There is little, if any, meaningful difference between dried blood 
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spots and other types of blood or tissue samples collected during clinical care; these differences 
between consent requirements are piecemeal and unaligned.  
However, it should be noted that, in the case of research using cell lines (i.e., a collection 
of “potentially immortal cells… that can continue to divide indefinitely”), some argue that 
different biospecimen types should be regulated differently, as some biospecimen types are more 
identifiable and pose more privacy risks to individuals than others.[62] Authors disagreed about 
when genetic information, which is almost certainly derivable from human biospecimens, was 
regulated as PHI. Some authors only considered genetic information as protected when it was 
linked to any of the eighteen HIPAA-specified identifiers.[33,44] Others considered genetic 
information as always potentially individually identifiable, and thus should always protected 
under DHHS requirements.[30] A recent study simulating attacks on databases containing 
patients’ deidentified health records and biospecimens found that as many as 26% of 
biospecimens could be reidentified.[64] Patients’ privacy may continue to be at risk so long as 
such disagreement and discrepancies in how residual clinical biospecimens and health data are 
shared remain. 
It is a legal and ethical ideal that residual clinical biospecimens and health data are 
always shared in accordance with applicable regulations and norms, and that patients will have 
autonomy and agency over if and how their biospecimens and health data are reused. However, 
there is considerable administrative and logistical burden for tracing and interpreting such 
decisions over time, physical location, and across jurisdiction.[35,52,65] When it comes to 
regulation and consent tracing, even opt-out mechanisms place sometimes insurmountable 
burdens on IRBs and biospecimen brokers in deciding which biospecimen resources cannot be 
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shared.[66] The responsible conduct of research is challenged given the complexity of navigating 
these regulations and norms.  
While we agree that human interpretation of these permissions is not reasonable on a 
case-by-case basis, there is growing need for mechanisms to “flag” residual clinical 
biospecimens and health data as usable or unusable for a range of given activities, including 
research purposes.[65] To be scalable, knowledge and interpretations of regulations and norms 
concerning permissions to reuse specimens need to be represented in standardized, computable, 
and interoperable formats. No such resource presently exists, which is regarded as a major 
challenge to collaborations in biospecimen research, within the US and particularly 
internationally.[67,68] Future work should focus on development of such an interoperable 
resource (e.g., an ontology) to support responsible reuse of residual clinical biospecimens and 
health data. 
We recognize several limitations of this scoping review. We reviewed the biomedical, 
legal, and health ethics and policy literature to identify and summarize experts’ interpretations on 
how residual clinical biospecimens may be reused in the US. In doing so – rather than 
identifying and analyzing the regulations and norms directly – it is possible that we may have 
missed regulations or norms relevant to reusing residual clinical biospecimens and health data in 
the United States. We likewise may have missed relevant literature by searching within domain-
specific databases rather than multidisciplinary databases such as Scopus or JSTOR. Lastly, this 
review did not include a legal or ethics expert, and it is possible that our interpretation of the 
authors’ discussions may be incomplete or have unrecognized bias. 
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5. Conclusion 
The results of this review demonstrate the patchwork of ill-aligned and occasionally 
conflicting sources of authority and guidance. Considering such complexity, it is expectedly 
difficult for those who safeguard residual clinical biospecimens and health data to manage, 
interpret, and apply information from all applicable regulations and norms. While further 
clarification, harmonization, and alignment is necessary at both national and international scale, 
development of a computable resource which references permissions from these regulations and 
norms could support consistent, expert-informed, and responsible reuse of residual clinical 
biospecimens and health data. 
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Chapter 3 Development and Testing of an Annotation Scheme for Identifying 
Permissions within Clinical Consent Forms 
1. Introduction 
1.1. Background and Significance. 
 Informed consent is woven into the fabric of contemporary healthcare. In the context of 
clinical care, informed consent is the process by which clinicians disclose information to patients 
or their proxies so they may voluntarily choose whether to grant permission for or refuse a given 
procedure or treatment, and activities performed either directly or incidentally related to the 
procedure or treatment.[69] Clinicians are ethically and professionally obligated to obtain 
consent in advance of clinical procedures; not obtaining consent is legally considered an act of 
negligence or battery.[70,71] Documentation of the informed consent process must be included 
in patients’ health records, including copies of signed consent forms, whenever possible, as 
evidence of patients’ express permission.[71]  
Currently, permissions are not easily discoverable in automated modes, due in part to 
their many formats. Identification of these permissions is typically only available through 
processes such as manually retrieving and reviewing informed consent forms.[72] Consent forms 
remain “locked away” in non-machine readable files (e.g., scanned image files of paper-based 
consent forms), non-standardized eConsent forms, or as paper copies in physical storage. This 
means that for each downstream decision which references patient-granted permissions there is 
typically a manual process to review and interpret patient-granted permissions. While there are 
information systems that may record patient’s permissions, it is still a manual process to read and 
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interpret permissions and enter a value for the permission status in the information system. Even 
when the value is entered in the information system, the absence of standard representations of 
permissions presents challenges to information sharing.  
While manual review may be reasonable when searching for permissions from a specific 
patient, the lack of machine-interpretable representations of consent precludes the development 
of tools which search and identify such information at scale, i.e. across many consent forms. As 
an example, when patients sign consent forms during clinical care, these forms may contain 
additional permissions to reuse their residual clinical biospecimens and health data for secondary 
purposes. Should an investigator or other entity wish to access these materials, some human 
broker must access and interpret the consent form, also accounting for the complex environment 
of regulations and norms at multiple jurisdictions (i.e., institutional, state, federal, international 
norms), prior to acting on the request to access materials. If machine-interpretable and 
interoperable representations of permissions existed, tools which reference this information may 
increase the discovery of and access to biospecimen and health data resources for scientific 
discovery, while also respecting specimen contributors by observing and heeding how they 
choose and permit their biological material and to be used.[73] 
Before such tools can be developed, a requisite first step is to ensure that humans can 
reliably identify permissions as they appear in real-world consent forms. Creating a human-
readable blueprint (i.e., annotation scheme) for manual discovery of the permissions in consent 
forms also enables quantitative comparison of the reliability of annotations between 
annotators.[74] Because of the complexity of the phenomenon and the heterogeneity of 
permissions as they appear in consent forms, it is important to start with manual annotations to 
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ensure that the full scope of permissions are discovered, and to create a preliminary dataset for 
training automated annotation or text processing tools.[75]   
1.2. Objective.  
The purpose of this study was to develop and test an annotation scheme for identifying 
permission-sentences within clinical consent forms. This study was a part of a larger 
investigation focused on modelling permissions to reuse residual clinical biospecimens and 
health data for secondary, non-clinical purposes. Permissions identified through this study will 
inform the extension of The Informed Consent Ontology (ICO), a machine-readable, semantic 
resource  for representing consent processes, including permissions granted during such 
processes. ICO was originally developed to reflect research consent processes, and we propose 
that ICO may can be extended to provide a common resource for the development of multiple 
resources that require interoperable representations of permissions (e.g., text processing systems, 
at-scale information systems that that are aware of consent and permitted actions) across both 
research and clinical contexts. 
2. Methods 
 2.1. Design.  
This was a retrospective analysis of existing clinical consent forms. Three members of 
the research team were involved throughout the entirety of the data analysis and annotation 
process: the principle investigator (PI; a nurse scientist), a trained research assistant (RA; 
provided a healthcare consumer perspective), and a practicing registered nurse (RN; provided a 
healthcare clinician perspective). In addition, a data scientist with experience in text processing 
was engaged to support the technical requirements of the annotation effort. Institutional Review 
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Board review was not required because human subjects and their data were not involved in this 
analysis; only blank, unsigned consent forms were collected and analyzed.  
 2.2. Sampling Strategies. 
Consent forms were collected using two methods: direct contribution by healthcare 
facilities and systematic web searching. Direct contribution involved convenience sampling [76] 
by soliciting voluntary contribution of consent forms from healthcare facilities. With support 
from leadership within the Michigan Health Information Management Association (MHIMA), a 
recruitment email was sent to twenty-nine directors of health information management 
departments who were members of MHIMA. Because we could not assume that this limited 
sample was representative of health care facilities broadly, we chose to supplement our sample 
with the following purposive sampling approaches.  
First, case sampling – cases that are representative of the typical or average [76] – was 
conducted by randomly selecting healthcare facilities from two U.S. government published, 
open-access lists. Two hundred facilities were randomly selected from a list of all hospitals 
registered with Medicare [77], and 50 facilities were randomly selected from a list of all 
ambulatory surgical centers participating in the Ambulatory Surgical Center Quality Reporting 
Program.[78] These lists included facilities’ names, unique identifiers, location information, 
hospital type (critical access, acute care, children’s, or psychiatric), and hospital ownership (e.g., 
proprietary, government, non-profit, etc.).  
Second, criterion sampling [76] was used to discover clinical consent forms from 
academic medical centers associated with Clinical and Translational Science Award (CTSA) 
hubs funded for the years 2014-2018.[79] CTSA hubs are research institutions “that work 
together to improve the translational research process to get more treatments to more patients 
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more quickly.”[79] We selected the criterion of healthcare facilities affiliated with CTSA hubs 
based on the assumption that, because their mission includes biomedical and health research, 
their clinical consent forms may be more specific in requesting permission to reuse residual 
clinical biospecimens and health data for secondary purposes (such as research) than forms from 
other facilities. Although some CTSA hubs were associated with multiple healthcare facilities, 
only one facility was selected for each CTSA hub (i.e., a one-to-one match; n= 63), typically the 
affiliated academic medical center or first facility listed by the CTSA on its website. 
 2.3. Consent Form Management  
  2.3.1. Data Collection. 
Per directions sent by email to the MHIMA members, consent forms were emailed to the 
PI directly or through our MHIMA partner as an intermediary. All consent forms were saved as 
PDFs, some as native files and others as scanned images of hard copies of forms. One facility 
gave our team permission to download consent forms directly from their internal health 
information management website, which the PI had access to as an employee of that facility. 
For each of the web-identified healthcare facilities (i.e., randomly selected hospitals, 
randomly selected ambulatory surgical centers, and facilities affiliated with CTSA hubs), a two-
fold internet search strategy was used. First, facility names and locations were used to query 
Google and identify each site’s website, if available. Queries for “consent form” were submitted 
in the websites’ internal search tools, and webpages with patient resources were reviewed for 
consent forms. Second, a combination of facility names, locations, and “consent form” were used 
to query Google for any publicly available consent forms not yet retrieved through the website 
searches. Forms were retrieved if they included a request to conduct any clinical care process or 
procedure (i.e., therapeutic or diagnostic). If the relevance of a form was not immediately clear, 
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the form was retrieved and later screened. Again, we did not search for consent forms that were 
developed for specific research projects. This study focuses on consent forms for clinical 
procedures, and our interest is identification of permissions for research use of residual 
biospecimens. 
  2.3.2. Data Management, Transformation, and Curation 
We established separate folders for archiving downloaded forms according to each 
sampling approach. Digital files of all consent forms and corresponding documentation were 
stored using a Business Associate Agreement (BAA) compliant cloud-based storage service (i.e., 
Box). Files were only accessible to members of the research team and, for all files that were not 
publicly available (i.e., facility-contributed), facilities’ identifiers (e.g., logos, names) were 
obscured.  
Records containing descriptive information about selected facilities and identified forms 
were entered into Excel spreadsheets. For all internet searches, the following metadata were 
generated: if the facility’s website was found (yes/no), number of forms discovered, and the 
curator’s field notes. For each discovered consent form, file name, header or title of the form, 
search terms used, URL, date uploaded (if available), date last modified (if available), date 
retrieved, and if the document was a consent form template (yes/no) was documented. Facility 
metadata assigned by Centers for Medicare and Medicaid Services, including unique identifiers, 
name, location, facility type, and facility ownership, were mapped to and recorded for each form. 
  2.3.3. Screening for Inclusion 
All retrieved consent forms were screened for inclusion based on relevance to this study. 
Forms were included in the analysis if they documented permission for clinical procedures (e.g., 
diagnostic, therapeutic, general/admission). Forms were excluded if they were duplicates of other 
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retrieved forms, were for hospital operations or other non-clinical purposes (e.g., health 
information exchange, payment, research), were written in languages other than English, or were 
not human-readable after optical character recognition (OCR) and conversion to .txt file. For 
large, many-page files that contained multiple forms with varied purposes (e.g., a patient 
registration or preoperative packet), the screeners selected which pages should be included in the 
final sample and omitted pages according to the eligibility criteria. Screening occurred 
independently by the PI and RA, i.e., decisions regarding inclusion vs. exclusion were blind to 
the other reviewer. Eligibility decisions were discussed by the PI and RA, and disagreements 
were settled by deliberation the PI’s graduate supervisor. See Figure 2 for a summary of data 
collection and management procedures.  
 2.4. Annotation Scheme Development and Testing 
  2.4.1. Annotation Scheme Development. 
We followed Pustejovsky and colleagues’ MAMA (Model-Annotate-Model-Annotate) 
cycle as the method for developing and refining our annotation scheme (see Figure 3).[80] That 
is, after the study team proposed an initial set of instructions for annotations, the annotators 
applied those instructions using a small subset of the data, the PI and data scientist tested and 
evaluated the reliability of those annotations across annotators, and the study team revised the 
annotation scheme based on these findings. In iteratively completing these steps, we refined the 
specifications within the annotation scheme, increasing the clarity for human-interpretation of 
the annotation scheme and, ultimately, the quality of their downstream annotations. Our 
annotation scheme was informed by deontic logic as it informed ICO.[81] Deontic logic is a 
branch of logic rooted in representations of normative statements (i.e., what ought to be) and 
includes the notions of permission, obligation, and prohibition.[82]   
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Figure 2. Data Collection and Management Procedures 
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Figure 3. MAMA cycle for annotation scheme development.  
Reprinted from “Designing Annotation Schemes: From Theory to Model.” Pustejovsky J, Bunt H, Zaenen A. In: Ide N, 
Pustejovsky J, editors. Handbook of Linguistic Annotation. Dordrecht: Springer Netherlands; 2017. p. 21–72. 
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To begin, two team members independently reviewed five randomly selected consent 
forms using the prompt, “Identify any content within the forms that would be essential to 
understand what was consented to.” Whereas the PI marked up large blocks of text including 
descriptive content, signature lines, and facility information, the RA only marked up what she 
called “consent language.” Consent language was verb phrases indicating the act of consent; 
such phrases included: agree that, consent to, hereby authorize, request that, etc. When 
examining the overlap of the PI’s and RA’s markup, we noticed that the RA’s consent language 
almost always was included in the larger blocks of text marked by the PI.  We subsequently 
decided to limit the annotation task to only those overlapping sentences. We identified these as 
“permission-sentences” which were direct statements within the consent form that, when the 
form was signed by the patient or their legally authorized representative, permitted the healthcare 
facility or its clinicians to do some action or activity.  
We iteratively annotated unique sets of five randomly selected consent forms at a time, 
manually comparing our output after each iteration and adapting the annotation scheme to clarify 
its specifications. We found that the number of permission-sentences and their structure and 
content varied by consent documents. After five iterations, in which we met to review 
annotations and revise the annotation scheme to clarify procedures, the research team agreed that 
reasonable agreement was achieved based on qualitative evaluation.  
The final definition for permission-sentences was, “statement(s) that, upon signature of 
the consent form, authorizes any new action or activity that may, must, or must not be done.” 
While broad, this definition allowed us to discriminate permission-sentences from those that do 
not allow or require some new action or activity, such as descriptions of care, statements that 
reinforce patients’ rights, etc. We did not annotate sentences that included agreements or 
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permissions related to payment or other hospital operations (e.g., “In consideration of the 
services provided at the Hospital, I agree to pay the Hospital, my physician(s) and other 
professionals involved in my care for all services, facilities and supplies provided to me.”) The 
tag A:Is was used to annotate sentences that annotators were certain were permission-sentences 
(i.e., This is a permission-sentence). Due to complex and inconsistent language across consent 
forms, we also chose to allow for annotator uncertainty in identifying permissions, denoted by 
the tag B:MightBe (i.e., This might be a permission-sentence). Appendix C includes the complete 
final annotation scheme. For all sentences not tagged by the annotator, we forced automatic 
encoding of a third tag, C:Not (i.e., This is not a permission-sentence). Because the language of 
permission-sentences is often ambiguous and dependent on context, we allowed annotators to 
identify a level of uncertainty but did not impose criteria regarding what made them uncertain. 
This decision was made with the goal of being as inclusive as possible. 
  2.4.2. Data Preprocessing. 
All consent forms were converted from their original file format (most often .pdf files) to 
text files (.txt) using optical character recognition (OCR) and conversion tools built into Adobe 
Acrobat DC or MS Word (for .doc). Text files were uploaded to DataTurks, an open-source web-
service annotation platform. Three annotators used DataTurks and the developed annotation 
scheme to markup sentences in consent forms, and their level of certainty that a given sentence 
was a permission-sentence. (See annotation scheme in Appendix C.) 
While the DataTurks software was easy for annotators to learn and use, considerable pre-
processing of files exported from DataTurks was required prior to calculating agreement 
statistics at the sentence level for multiple annotators and labels. We first constructed a pipeline 
written in Python 3.7 for processing DataTurks’ export files (lists of .json objects). We forced 
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standard character encoding (‘ASCII’) for all documents and replaced all non- ASCII characters 
(such as Chinese characters) with spaces (whitespace characters). We removed signature line 
characters (‘_’) and redundant white space characters. The result of these preprocessing steps 
was a data structure that contained (a) the full raw text of the consent forms (as a string), (b) a 
list of annotations, and (c) metadata about each annotation task. Each annotation in (b) was 
further broken down into the annotated text string, starting and ending character positions 
relative to the character counts in the consent form, and the assigned label for each annotator. 
Parts (a-c) of the data structure were separated by annotator. 
We then used spaCy, an open-source software library for natural language processing, to 
parse the raw text files in order to generate a list of all sentences for each informed consent form. 
We employed the pre-trained word vectors from the En_core_web_lg model. This semantic 
model was used to detect sentence boundaries and was trained on OntoNotes Common 
Crawl.[83] Sentence parsing using the spaCy default parsing logic resulted in 9951 sentences 
across all forms (n=134). Due to the noise introduced by OCR and heterogenous sentence 
structures across consent forms (e.g., header phrases with bullets and other symbols rather than 
full sentences) we excluded parsed text identified by spaCY as a “sentence” if the text lacked any 
English alphabet characters, was less than nine characters long, or was less than three words 
long. These data cleaning steps resulted in a final set of 6399 sentences, from across the 134 
consent forms. These sentences served as reference for the sentences that were marked up by 
each annotator.  
We next developed an approach to align individual annotations by multiple annotators to 
the spaCy-parsed sentences. First, we aligned all annotations that matched a sentence in the 
informed consent form exactly. For those annotations that did not have exact matches, we 
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resorted to fuzzy matching using an implementation of Gestalt pattern matching algorithm.[84] 
This algorithm finds the longest contiguous matching subsequence, then recursively matches the 
remaining unmatched elements, in this case words. Using this approach, we were able to align 
annotations from multiple annotators to a given spaCY-identified sentence in the informed 
consent document. These steps yielded two data structures: (a) a document-map containing the 
raw consent forms and their sentence-parsed representations, and (b) a tabular structure where 
each record (row) was a spaCy-parsed sentence text span and metadata relating to that text span, 
and three columns reflecting the three annotators, so that the value of each cell in the table 
corresponded to the assigned label its corresponding annotator.  
The ease of use of DataTurks by the annotators was somewhat offset by the considerable 
amount of data preprocessing necessary to conduct the analysis. While we evaluated other freely 
available annotation tools, there were limitations to each that would have introduced other types 
of data cleaning procedures prior to analyzing inter-rater agreement.  
  2.4.3. Annotation Evaluation. 
We evaluated inter-annotator agreement of permission-sentence annotations using 
multiple methods. The first approach was to calculate raw or observed agreement (denoted as 
Ao) by summing the count of agreed upon annotations for all tags and dividing by the count of all 
sentences. Although easy to calculate and easy to understand, output of this measure does not 
take accidental agreement into consideration. This bias was particularly evident in cases when 
annotated categories are sparse.[85] We therefore also calculated coefficients which demonstrate 
the level of inter-annotator agreement beyond what was attributable to chance or arbitrary 
annotation. Table 3 provides benchmarks for interpreting agreement coefficients. 
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We first calculated Cohen’s 𝜅𝜅 to provide the proportion of agreement between annotators 
when treating categories as categorical.[85] However, A:Is, B:MightBe, and C:Not can also be 
conceptualized as rank-ordered, ranging from strongly agreeing that a given sentence is a 
permission sentence (A:Is) to strongly disagreeing that a given sentence is a permission-sentence 
(C:Not) with a neutral option allowing for uncertainty in the middle (B:MightBe). As such, we 
calculat weighted kappas (𝜅𝜅𝑤𝑤) to account for greater disagreement between A:Is and C:Not than 
between A:Is and B:MightBe or B:MightBe and C:Not. While Cohen’s 𝜅𝜅 treats all disagreements 
equally; 𝜅𝜅𝑤𝑤 quantifies the amount of agreement between categories.[86] We likewise calculated 
inter-annotator agreement across all three annotators, using Krippendorff’s α for agreement 
across categories of tags (categorically coded variables) and the amount of difference between 
categories (ordinally coded variables).[85] All statistical analyses were performed using R for 
Statistical Computing,[87] particularly the psych and irr packages.  
Lastly, because of the conceptual overlap of the tags (i.e., A:Is indicates annotators’ 
certainty for identifying a permission-sentence while B:MightBe encodes uncertainty around the 
same phenomenon of interest), we also chose to evaluate agreement by combining A:Is and 
B:MightBe into a single class (tag A=B). Cohen’s 𝜅𝜅 and Krippendorff’s α were recalculated 
using this approach. While acknowledging this approach may introduce false positives, this 
approach allowed us to be highly inclusive of all potential permission-sentences regardless of 
certainty of the annotators. This information will be useful in future refinement for automatic 
annotation.  
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Landis & Koch, 1977 [88] Koo & Li, 2017 [89] 
<0.00 Poor -- -- 
0.00-0.20 Slight -- -- 
0.21-0.40 Fair <0.50 Poor 
0.41-0.60 Moderate 0.50-0.75 Moderate 
0.61-0.80 Substantial 0.75-0.90 Good 
0.81-1.00 Almost Perfect >0.90 Excellent 
Table 3 Benchmarks for Interpreting Inter-annotator Agreement Coefficients. 
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3. Results 
The final dataset included 134 clinical consent forms. These forms were retrieved from 
62 unique healthcare facilities, which predominately included acute care hospitals (n= 48). Table 
4 describes the forms discovered by facility type. Although we only identified one form for most 
healthcare facilities (n= 39), the average number of consent forms by facility was considerably 
higher (𝜇𝜇= 4.25). This is largely explained by three outlier facilities which yielded a higher 
number of forms: Saint Marcy Mercy (n=13), University of Michigan (n=16), and Strong 
Memorial Hospital (n=16). Forms from Saint Mary Mercy and University of Michigan were 
collected through contribution from MHIMA facilities (i.e., they were not publicly available), 
while Strong Memorial Hospital’s consent forms were discovered online. Figure 4 depicts the  
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Table 4. Forms per Facility Types 
Facility Type 
 Unique 
Facilities 
Consent Forms per Facility 
 Total Forms Min Max Median Mode Mean 
Acute Care Hospitals 48 1 16 1 1 4.61 113 
Children’s Hospitals 1 1 1 1 1 1 1 
Critical Access Hospitals 4 1 2 1.5 2 1.5 6 
Psychiatric Hospitals 3 1 1 1 1 1 3 
Ambulatory Surgical Centers 6 1 3 2 2 1.83 11 
Total Sample 62 1 134 1 1 4.25 134 
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Figure 4. Distribution of facilities by number of forms included in the analysis. 
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right-skewed distribution of number of identified forms by facility. A complete list of facilities, 
their location, ownership, sampling strategy used to identify forms, and number of forms 
included in the final sample is provided in Appendix B.  
After preparing the data, the final corpus included 6399 sentences from across the 134 
forms. Consent forms varied widely in length, ranging from 4-432 sentences with an average of 
47.75 sentences per form. Of these 6399 sentences, 739 (11.5%) were annotated as possible 
permission-sentences (i.e., A:Is or B:MightBe) by at least one annotator; 5660 (88.5%) were not 
annotated by any annotator and therefore was assigned the label of C:Not by default. All three 
annotators identified 211 permission-sentences (28.6% of possible permission-sentences, 3.3% 
of total corpus) using A:Is, and at least two of the annotators identified 351 sentences (47.5% of 
possible permission-sentences, 5.5% of total corpus) using this label. Table 5 depicts the number 
and proportion of permission-sentences as the threshold for agreement was relaxed.  As 
expected, the count of permission-sentences diminishes as the threshold for agreement increases. 
Note that the number of sentences annotated as A:Is (n= 635) and B:MightBe (n=139) do not add 
to 739. This was explained by one annotator marking a given sentence with A:Is and another 
annotator marking the same sentence as B:MightBe. Sentences could be counted multiple times 
on this table.  
Table 6 compares inter-annotator agreement measures, including percent observed 
agreement (Ao), Cohen’s 𝜅𝜅 and 𝜅𝜅𝑤𝑤, Krippendorff’s α, and their associated confidence intervals. 
Observed agreement (Ao) was greater than 93% for all combinations of annotators (pairs and 
between all three). Agreement coefficients are presented for all combinations of annotators. The 
highest pairwise agreement was achieved between PI and RN (𝜅𝜅 = 0.6165; 𝜅𝜅𝑤𝑤 = 0.6546), 
followed by PI and RA (𝜅𝜅= 0.5606; 𝜅𝜅𝑤𝑤= 0.6040, then RA and RN (𝜅𝜅= 0.5466; 𝜅𝜅𝑤𝑤= 0.5796).  
 
 49 
Krippendorff’s α was 0.5737 when treating labels as categorical, and 0.5988 when treating labels 
as ordinal. These values reflect moderate agreement to substantial agreement.[88] 
As previously discussed, we also evaluated agreement while treating A:Is and B:MightBe 
as equivalent (henceforth A=B). Although annotators varied in their certainty when assigning 
labels, we observed an overall increase in agreement when combing A:Is and B:MightBe labels 
(α= 0.5927) compared to analysis of A:Is, B:MightBe, and C:Not categorically (α= 0.5737), but 
not higher than analysis of the three label ordinally (α= 0.5988). Tables 7 and 8 describe the 
annotations and inter-annotator agreement when using A=B. 
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Table 5. Identification of permission-sentences based on number of annotators. Percentages indicate the proportion of identified 
sentences to possible permission-sentences (n= 739) and the entire corpus (n=6399). 
 
Agreement by 3 
annotators 
Agreement by ≥2 
annotators 
Annotation by ≥1 
annotator 
A:Is: This is a  
permission-sentence 
211 351 635 
211/739 (28.6%) 351/739 (47.5%) 635/739 (85.9%) 
211/6399 (3.3%) 351/6399 (5.5%) 635/6399 (9.9%) 
B:MightBe: This might be a 
permission-sentence 
0 5 139 
0/739 (0%) 5/739 (0.7%) 139/739 (18.8%) 
0/6399 (0%) 5/6399 (0.0%) 139/6399 (2.1%) 
C:Not: This is not a 
permission-sentence 
5660 6028 6168 
-- -- -- 
5660/6399 (88.5%) 6028/6399 (94.8%) 6168/6399 (96.4%) 
   
Total Sentences 
6399 
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Table 6. Agreement measures among subgroups of and all annotators.  
Note: Agreement is reported using all labels (A:Is, B:MightBe, and C:Not). Ao is observed agreement, Ae is expected agreement 
or agreement by chance, and κ is the Kappa coefficient used to measure inter-annotator agreement, taking both Ao and Ae into 
account. Cohen’s κ is used to measure inter-annotator agreement between pairs of annotators, and Krippendorff’s α is used to 
measure inter-annotator agreement across all three annotators. 
  A:Is, B:MightBe, C:Not (n= 6399) 
  Categorical Ordinal 
  Ao Cohen's 𝜅𝜅 95% CI 𝜅𝜅𝑤𝑤 95% CI 
PI-RA 0.9444 0.5606 0.5212-0.6001 0.6040 0.4152-0.7928 
RA-RN 0.9373 0.5466 0.5078-0.5854 0.5796 0.3722-0.7869 
RN-PI 0.9509 0.6165 0.5787-0.6544 0.6546 0.4586-0.8506 
  𝐴𝐴𝑜𝑜���� Krippendorff’s α  95% CI Krippendorff’s α 95% CI 
PI-RA-RN 0.9442 0.5737 0.5425-0.6028 0.5988 0.5656-0.6309 
 
  
 52 
Table 7. Identification of permission-sentences based on number of annotators. Percentages indicate the proportion of identified 
sentences to possible permission-sentences (n= 739) and the entire corpus (n=6399). 
 
Agreement by 3 
annotators 
Agreement by ≥2 
annotators 
Annotation by ≥1 
annotator 
A=B: This [is/might be] a 
permission-sentence 
231 371 739 
231/739 (31.3%) 371/739 (50.2%) 739/739 (100%) 
231/6399 (3.6%) 371/6399 (5.8%) 739/6399 (11.5%) 
C:Not: This is not a permission-
sentence 
5660 6028 6168 
-- -- -- 
5660/6399 (88.5%) 6028/6399 (94.8%) 6168/6399 (96.4%) 
   
Total Sentences 
6399 
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Table 8. Agreement measures among subgroups of and all annotators.  
Note: Agreement is reported based on treating A:Is and B:MightBe as equivalent (A=B, C:Not). Ao is observed agreement, Ae is 
expected agreement or agreement by chance, and κ is the Kappa coefficient used to measure inter-annotator agreement, taking 
both Ao and Ae into account. Cohen’s κ is used to measure inter-annotator agreement between pairs of annotators, and 
Krippendorff’s α is used to measure inter-annotator agreement across all three annotators. 
  A=B, C:Not (n=6399) 
  Ao Cohen's 𝜅𝜅 95% CI 
PI-RA 0.9483 0.5881 0.5479-0.6282 
RA-RN 0.9389 0.5550 0.5157-0.5943 
RN-PI 0.9541 0.6385 0.6003-0.6767 
  𝐴𝐴𝑜𝑜���� Krippendorff’s α 95% CI 
PI-RA-RN 0.9471 0.5927 0.5589-0.6243 
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4. Discussion 
The purpose of this study was to develop and test an annotation scheme to identify 
permission-sentences within clinical consent forms. Consent forms include essential information 
about what activities were permitted by the signers. However, this information is often 
inaccessible to computable information systems. One way to approach the extraction of this 
information from consent forms is through text processing. While the presented results may not 
yet be sufficient for information retrieval tasks, this work provides a foundation for discovering 
potential permission-sentences in new samples of consent forms at a larger scale. Automated 
classification models for discovery of potential permission sentences may yield data necessary 
for further developing and iteratively revising the annotation scheme downstream. This is the 
first study we are aware of that has attempted to identify permission-sentences within clinical 
consent forms.  
The developed annotation scheme and process yielded moderate to substantial reliability 
in providing guidance on identifying permission-sentences. Overall, these results should be 
interpreted cautiously and acknowledgement given that disagreement or uncertainty around 
identifying permission-sentences may be the result ambiguously written consent forms. 
Agreement was highest when evaluating labels, A:Is, B:MightBe, and C:Not using a weighted 
Kappa statistic. This is explained by the label, B:MightBe – which encodes the annotators’ 
uncertainty about assigning either of the two labels – is more similar to the other two classes than 
A:Is and C:Not are to each other. We also tested the combination of classes (i.e., A=B vs. C:Not) 
with improved results compared to the unweighted kappa, but these results were not superior to 
the weighted kappa. By using the weighted kappa, we reduce the quantitative penalty for 
annotators disagreeing about which particular instances they were uncertain about classifying 
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using an A:Is or C:Not label. Despite use of B:MightBe by all annotators, very few sentences 
were classified with this label by any two annotators (n= 5) and none by all three annotators. 
Artstein reminds us that when labels share similarity or overlap, “it may make sense to test 
reliability at multiple levels at once, since working at multiple levels reflects the process the 
annotators go through when making their choices.”[85] By providing multiple analyses, we 
demonstrate the complexity of identifying permission-sentences within consent forms.  
When examining pairwise agreement between annotators, agreement was highest 
between the PI and RN, and lowest between the RA and RN. However, the difference in 
agreement between pairs of annotators was minimal. Slightly higher agreement between the PI 
and RN may be explained by both having health care clinician backgrounds, i.e. they may have a 
different view of health care consent processes than the RA, who is representative of the health 
care consumer perspective. It is arguable that “since these [documents] are written by [those with 
health care perspective], it is reasonable to assume that in this case, the [health care provider’s] 
interpretation is a better reflection of the writer’s intention.”[85] Whereas reliability of 
annotations may benefit from only using clinicians in the future, this does not bode well for the 
nature of the consent forms themselves – which should be ethically understandable by lay 
readers and health care consumers.[90]   
We found that it was difficult to obtain clinical consent forms. Few facilities responded to 
a direct request for consent forms (13.8%, n= 4), and only 18.5% (n= 58) of randomly and 
purposively sampled facilities made their consent forms publicly available on the web. There are 
known reasons for this; Retrievability of consent forms may often be blocked for legal, risk 
management, or proprietary protections.[91] As such, those consent forms that are published 
may reflect biased selectivity or projection of the values and attributes of the healthcare facilities 
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that publish their forms. It warrants questioning that so few clinical consent forms are made 
publicly available when the basis of consent in healthcare is rooted in beneficence, transparency, 
and trust.[69,92] Furthermore, in research contexts, open access to consent forms is a clearly 
articulated goal.[93,94]  
As an incidental finding, we observed that permission-sentences which specified reuse of 
residual clinical biospecimens and health data predominately permitted these activities without 
restriction or description of the future reuses, which merits further investigation. During recent 
debates about informed consent within human subjects research, consent to all future research 
without limitations or conditions was deemed unethical as it could not possibly be considered 
“informed.”[37,95,96] As such, the 2018 revisions to the Common Rule instead prescribe 
inclusion of specifications, categories, and purposes of future research, now referred to as “broad 
consent.”[11] Although standards for clinical consent specify that complete information about 
diagnosis, plan of care, alternatives, and risks be enumerated, there is no broadly enforceable 
consent requirements to protect patients whose residual clinical biospecimens or health data may 
be used for downstream purposes.[92] In our sample of consent forms, when permission to reuse 
residual clinical biospecimens or health data were specified, this permission was linked to all 
other permissions in the form, without a traceable method that allowed patients to consent to 
some permissions but not all. As currently practiced, informed consent “does not offer the 
granularity that is required for data donors to exert meaningful control.”[10] In addition, some 
authors have identified that patients prefer that they be able to permit or forbid individual actions 
or activities, and not have multiple permissions be aggregated in an “all-or-nothing” consent 
form.[7]  
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This project lays an important foundation for automated discovery of potential 
permission-sentences within clinical consent forms. The next step, machine-interpretation of 
identified permissions, further requires a semantically rich knowledge base (i.e., ontology) and 
mapping of consent information to that knowledge base. Identified permission-sentences from 
this study will serve as input to testing and extending the Informed Consent Ontology for 
representation of clinical consent processes. The internal structure of permission-sentences must 
also be further deconstructed and modeled so that information about permissions can be mapped 
to ICO classes and enable downstream queries and inferencing based on permissions. While 
there is important work underway to standardize consent statements going forward (e.g., 
GA4GH and HL7) those efforts are grounded in research consent forms. They may however be 
useful to clinical consent forms. Even should such clauses become standardized, there will 
remain a need to support more automated processes to manage permissions in existing consent 
forms.  
Other future work should include refining a final list of permission-sentences which will 
serve as training data for automated text processing of clinical consent forms to identify 
permission-sentences, and later classify these sentences according to their content.[97] 
Automatic annotation, which largely employs rule-based methods or training a model to identify 
a phenomenon of interest, requires extensive programing or training of the tagging system.[75] 
Model training requires machine learning from set of reliably-detected instances of a 
phenomenon so that future instances can be detected from new data sources.[98] While our 
results demonstrate moderate to substantial inter-annotator agreement, enhancement of the set of 
identified permission-sentences is yet needed before automated text processing can be performed 
reliably.[97] 
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Our findings point to the complexity of identifying permission-sentences within the 
forms. While it is known that incomprehensibility of clinical consent forms is ubiquitous,[99] 
our findings may also point to such complexity and obfuscation within the forms that even two 
clinicians (PI and RN) had difficulty identifying permission-sentences within the sample of 
forms. Future research should examine the understandability permissions in consent forms to 
determine if signers, clinicians, and form authors can reliably agree regarding which sentences 
permit some new action or activity, and later which actions or activities are being permitted. 
Further work might also include standardization of clinical consent forms and their content, with 
emphasis on increasing their understandability by patients and clinicians alike. 
This study has several limitations. First, it is unknown whether the sample is broadly 
representative of clinical consent forms, or if bias was unintentionally introduced to the sample 
through collection of publicly available consent forms. Access to certain types of documents are 
often blocked for legal or proprietary protections, and those that are published may suggest 
“biased selectivity” or projection of the values or attributes of the units that publish the 
documents.[91] It was also not possible to determine if the consent forms retrieved from the web 
were the most current version in use by the institution since most were not dated. Another 
limitation was that additional levels of error variance were not accounted for when calculating 
inter-annotator agreement because we did not nest permission-sentences by form or form by 
facility. It is possible that particular forms or facilities used language that was either highly 
agreed or disagreed upon by the annotators, at levels different from the annotations overall. 
Lastly, annotations by the developer of the annotation scheme and trainer of the RA (i.e., PI) 
may have introduced bias to the findings. Inter-annotator agreement is calculated under the 
assumption that annotators and their classifications are independent of one another.[88] This 
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limitation was addressed in-part by the PI not instructing the RA on how to interpret the 
annotation scheme, but rather iteratively revising it and pointing the RA back to the scheme 
during each annotation round. We also addressed this limitation by adding a third, untrained 
annotator (i.e., RN) whose classification of permission-sentences were, other than sharing an 
annotation guide, independent of the other annotators. 
5. Conclusion 
We developed and tested an annotation scheme for identifying permission-sentences 
within clinical consent forms that performed with moderate to substantial reliability among three 
annotators. The permission-sentences identified through this work will serve as the input for 
future modeling the structure of the internal structure and content of permission-sentences, and 
be iteratively enhanced to serve as a gold standard training set for natural language processing 
and automated-extraction of permission-sentences. Extending and leveraging the Informed 
Consent Ontology will contribute to laying a foundation for machine-interpretation of permission 
information in clinical and clinical research information systems. It will also contribute to 
scientific discovery by increasing the accessibility of materials and information resources that are 
permitted to be shared and protect patients by honoring their agency and decision-making around 
complex issues.  
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Chapter 4 Evaluating the Informed Consent Ontology for Coverage of Permissions to 
Reuse Residual Clinical Biospecimens and Health Data 
 
1. Introduction 
 1.1. Background and Significance 
Informed consent is a foundational requirement in both clinical care and research studies. 
The documentation of informed consent on forms serves as one source of evidence that an 
informed consent process occurred, and that the consenter has received enough information to 
make an informed decision regarding the permissions they are being asked to either grant or 
deny.[100] As the demand for vast and heterogeneous collections of human biospecimens 
increases, so does the frequency with which individuals are being asked if their biospecimens 
can be used for secondary purposes.[101] While considerable efforts are underway for tracing 
such permissions for biospecimens collected during research studies, significantly less attention 
has been given been given to clinical consent forms and permissions to reuse residual clinical 
biospecimens. These residual clinical biospecimens are those portions of biospecimens that 
remain after their clinical indications are fulfilled, and are recognized as an increasingly valuable 
resource.  
There is a need for increasingly capable information systems to facilitate the discovery, 
access, and responsible sharing and use of stored biospecimens and data, and to facilitate data 
integration and knowledge discovery within a contemporary connected research environment. 
This vision requires development of technology which supports expectations around FAIR 
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(Findable, Accessible, Interoperable, Reusable) Principles, including metadata that supports 
discovery of biospecimens and data according to their permitted and restricted uses.[102] 
Semantic web technologies such as ontologies hold great promise as an infrastructure solution 
for scalable, interoperable approaches in healthcare and research.[16] Ontologies enable 
integration of multiple bodies of data through ‘annotating’ their individual fields to the structural 
elements of a common ontology, which map knowledge in terms of entities and relationships in a 
domain. Many ontologies for the biomedical domain are published and in-use.[18,103] 
The Basic Formal Ontology (BFO) is realism-based, upper level ontology informed by 
the perspective that reality is independent of human experience, and the real world is comprised 
of objective entities.[104] BFO’s structure is composed of objects (i.e., continuants), processes 
(i.e., occurrents), and their relationships with time.[105] This common structure is the basis for 
enforcing logical rules across all ontologies which import or refer to BFO. As an upper level or 
reference ontology, BFO does not contain any physical, chemical, biological or other specialist 
terms.[106] Rather, the Open Biomedical Ontologies (OBO) Foundry is a family of ontologies 
aligned with a set of shared principles for ontology development. One core principle is use of a 
shared logical structure (i.e., BFO) of the ontologies as the source for common classes (i.e., the 
maximal collection of all particulars or instances of that thing) and object properties (i.e., the 
relationships which link classes). Other principles include open access and use, community-
based collaborative development, and non-overlapping and strictly-scoped content. The OBO 
Foundry enforces these design principles to achieve semantic interoperability, a strong and 
accurate logical basis, and scientific accuracy.[18,103]  
While multiple OBO Foundry ontologies are useful for representing information relevant 
to biomedical science and research, there is one ontology that is particularly relevant and may be 
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fit for use when representing relevant permissions in the context of clinical care – the Informed 
Consent Ontology (ICO). ICO was designed to represent documents and processes relevant to 
consent, specifically for biomedical and health research.[18,107] As currently published, the 
ontology contains class representations of processes such as signing an informed consent form 
and IRB (or other regulating body) approval of the consent form, as well as identifiers for the 
investigator and participant roles.[20] Development of ICO followed OBO Foundry principles 
and extends from the top-level Basic Formal Ontology (BFO), enabling its use a reference 
ontology (i.e., represents universals and relations) in this domain.[18,107,108] ICO, however, 
was not developed to represent the nuanced information relevant to consent in health care, 
including permissions to reuse residual clinical biospecimens and health data for secondary 
purposes. While some or all of the existing classes may be transferable to this new domain, ICO 
must be formally evaluated for reuse in this domain and extended or revised as necessary.  
This paper addresses the need to evaluate ICO for use in clinical consents. However, 
there are well-recognized challenges in ontology evaluation: namely that, despite more than a 
decade of publication on the issue, there continues to be no accepted standard methodology for 
ontology evaluation.[109,110] The scope of potential criteria by which ontologies are evaluated 
include “its coverage of a particular domain and the richness, complexity, and granularity of that 
coverage; the specific use cases, scenarios, requirements, applications, and data sources it was 
developed to address; and formal properties such as the consistency and completeness of the 
ontology and the representation language in which it is modeled.”[111] Overall, formal 
evaluation is underutilized in ontology development, leading to the release of poor ontologies 
and ultimately hindering “the successful deployment of ontologies as a technology.”[21] 
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Currently, systematic evaluation of ontologies require that evaluators assemble methods from 
across various evaluation schema. 
 1.2. Purpose 
The purpose of this study is to apply a hybrid model of ontology evaluation to ICO, with 
a specific focus of evaluating ICO for its completeness expressing permissions from regulations 
and clinical consent forms with a focus on reuse of residual clinical biospecimens and health 
data, and developing recommendations for extension and revision.  
2. Methods 
This study follows a formative evaluation design, in which we examine an information 
resource (ICO) under development.[112] We adapted Friedman and Wyatt’s multistep evaluation 
process to iteratively examine and check our findings, integrating key steps from the ontology 
evaluation literature. Figure 5 depicts our multistep evaluation process. Our analysis was also 
guided by evaluation methods and questions abstracted from the literature, including the 
National Institute of Standards and Technology’s (NIST) Ontology Summit’s guidance for 
evaluating ontologies across ontology life cycles.[21] Figure 6 presents the phases of the 
Ontology Life Cycle Model. Importantly, we solicited stakeholder involvement throughout the 
evaluation process, primarily ICO developers and the OBO foundry community.  
 
 64 
Figure 5. Multistep, Iterative Ontology Evaluation Process. 
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Figure 6. Ontology Life Cycle Model. 
Retrieved from Neuhaus, F., Ray, S., & Sriram, R. D. (2014). Toward ontology evaluation across the life cycle (NIST IR 8008). 
National Institute of Standards and Technology. 
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 2.1. Identify Life Cycle Phase 
Because our purpose was to evaluate any modifications to ICO necessary for representing 
permissions in clinical consent regarding residual clinical biospecimen and health data reuse, we 
entered ICO’s life cycle and this evaluation at the Ontology Development & Reuse Phase. The 
Ontology Development & Reuse Phase includes a focus on ontology adaptation to fit a new 
domain. Four primary evaluation tasks are recommended at this phase: informal modeling, 
formalization of competency questions, formal modeling, and operational adaptation.[21] 
Because this evaluation focuses on completeness (i.e., if the new domain is appropriately 
covered in the ontology),[113] we limit our analysis and reporting to informal modeling of 
content identified from relevant regulations and clinical consent forms.  
 2.2. Determine Evaluation Aims and Questions  
Consistent with both evaluation literature and the available ontology evaluation literature, 
evaluation often largely depend on the contribution and feedback of domain experts.[21,110] 
Accordingly, we developed evaluation aims and questions together with a community of ICO 
developers and OBO Foundry stakeholders. The questions guiding this evaluation were:  
A) Does ICO contain the necessary classes and relationships to represent permissions 
granted through US federal regulations to reuse residual clinical biospecimens and health 
data? 
B) Does ICO contain the necessary classes and relationships to represent permissions 
named in clinical informed consent forms, both for reuse of residual clinical 
biospecimens and health data and other clinical procedures? 
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 2.3. Iterative Investigative Loop 
The Iterative Investigative Loop is comprised of three steps: data collection, analysis and 
modeling, and reflection and negotiation. These steps are done both iteratively and in tandem 
with one another, enabling continuous revisiting of the data, revision of the models, and 
collaboration with stakeholders. 
  2.3.1. Data Collection  
Data collected and analyzed for this evaluation study included permissions to reuse 
residual clinical biospecimens and health data, abstracted from two sources. First, permissions to 
reuse residual clinical biospecimens provided through US Federal regulations were identified 
through a review of biomedical, legal, and health policy literature. By identifying these 
permissions through the literature, we attempt to reduce introducing our own biases into the 
information resource by instead extracting the interpretations of what is legally permissible by 
experts in their respective fields. The included regulations were: the 21st Century Cures Act, 
Affordable Care Act (ACA), Americans with Disabilities Act, Clinical Laboratory Improvement 
Act (CLIA), Common Rule, Food and Drug Administration Amendments Act (FDAAA), 
Genetic Information Nondiscrimination Act (GINA), Health Insurance and Portability and 
Accountability Act (HIPAA), Newborn Screen Saves Lives Reauthorization Act, Rehabilitation 
Act, and 42 U.S. Code § 241 Research and Investigations Generally. While the literature review 
additionally collected information about norms (e.g. best practices and guidance documents), we 
chose to limit the present evaluation to US Federal regulations because of the legal authority and 
weight they bear. Norms are important for guiding practice, but do not bear legal authority. 
Second, permission-sentences identified through an annotation study of clinical consent 
forms. Permission-sentences were eligible for inclusion if they were positively annotated as a 
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permission-sentences by three annotators of the consent forms. Of this collection of 211 
permission-sentences, a sample of 15 were included in this evaluation. Six permission-sentences 
were purposively selected because they expressly permitted sharing or reuse of residual clinical 
biospecimens or health data, i.e., the primary phenomenon of interest in this study. Four 
sentences were selected to for the heterogeneity of the activities they permitted (e.g. videotaping, 
surgery, anesthesia). Five additional sentences were randomly selected to account for and reduce 
potential bias introduced through purposive sampling. All permission-sentences included in this 
analysis are listed in Table 9. 
  2.3.2 Analysis and Modeling 
The goal of informal modeling is to identify all relevant ontological entities (including 
classes and relationships), the entities’ important attributes, and appropriate terminology for the 
new domain. These results are then modeled in an informal way, such as through concept 
maps.[21]  
We started by looking at each of the identified permissions from the source data, both 
from US federal regulations and consent forms, and identifying all entities and relationships 
between those entities within each permission. We then referenced key parent classes modeled in 
ICO – including information content entity, material entity, process, and role – and began sorting 
the identified entities into these categories without defining them or their hierarchies. At the 
same time, we began graphically modeling the loosely defined classes from the consent forms 
and their relationships using a mind-mapping software. For regulations, we focused just on 
identifying classes rather than graphically modeling their relationships, as there is not yet a legal 
ontology in the OBO foundry, and we recognize that the complexity of regulations warrants 
intensive involvement by a legal domain expert. We carefully examined ICO and OBO foundry  
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Table 9. List of Permission-Sentences from Clinical Consent Forms which were included in this Evaluation.  
Note: By agreement with recruited facilities, we obscured facility names whose consent forms were not publicly available using 
XXX. For all facilities whose consent forms were publicly available, we did not remove identifiers. 
Purposively Sampled Permission-Sentences 
Reuse of Residual Clinical Biospecimens and/or Health Data 
1. I hereby authorize XXX to retain, preserve and use for scientific or teaching purposes, or to dispose at its 
discretion or convenience, any specimen or tissues taken from my body during my visit. 
2. I am a New York state resident and I give permission for GeneDx to retain any remaining sample longer 
than 60 days after completion of testing and use my de-identified data for scientific and medical research 
purposes. 
3. I DONATE and authorize XXX to own, use, retain, preserve, manipulate, analyze, or dispose of any excess 
tissues, specimens, or parts of organs that are removed from my body during the procedures described above 
and are not necessary for my diagnosis or treatment. 
4. I agree that any excess tissue, fluids or specimens removed from my body during my outpatient visit or 
hospital stay ( my specimens ) that would otherwise be disposed of by the Hospital may be used for such 
educational purposes and research, including research on the genetic materials (DNA). 
5. I authorize the pathologist, at his or her discretion, to retain, preserve, use, or dispose of any tissues, organs, 
bones, bodily fluid or medical devices that may be removed during the operation(s) or procedure(s).  
6. I hereby consent to the use and disclosure of my protected health information as described in the Notice of 
Privacy Practices. 
Other Clinical Procedures and Activities 
7. By signing this form, I am requesting and giving my consent for MHSM and the doctors and/or nurses to 
give me blood and/o blood products during this admission or series of treatments. 
8. Your signature below indicates that you understand to your satisfaction the information about the genetic 
testing ordered by your health care provider and that you consent to having this testing performed. 
9. I consent to the Facility videotaping, photographing, video monitoring, or taking other recordings of me or 
parts of my body for diagnosis, treatment, research, or patient safety purposes. 
10. I also consent to diagnostic studies, tests, anesthesia, x-ray examinations and any other treatment or courses 
of treatment relating to the diagnosis or procedure described herein. 
Randomly Sampled Permission-Sentences 
11. I, , request and consent to the start or induction of my labor by my provider: and other assistants as may be 
selected by him/her. 
12. I voluntarily consent to receive medical and health care services that may include diagnostic procedures, 
examination, and treatment. 
13. I consent to the use of closed-circuit television, taking of photographs (including videos), and the 
preparation of drawings and similar illustrative graphic material for scientific purposes providing my 
identity is not revealed. 
14. I hereby consent to engaging in virtual health/telemedicine services, where available, as part of my 
treatment. 
15. In the event a healthcare worker is exposed to my blood or body fluids in connection with my procedure, or 
during my hospital stay, I agree to the collection and testing of my blood for HIV. 
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 ontology classes in terms of their labels, textual definitions, and formal definitions for fidelity to 
their use in the context of US Federal regulations and clinical consent forms. These steps were 
performed both in tandem and iteratively until a final model for each individual permission from 
the source data was developed and vetted by multiple team members and collaborators. The 
resulting graphic models serve as representations of proposed design patterns for ICO.  
  2.3.3. Reflection and Negotiation 
As previously mentioned, methods for evaluation of ontologies is not mature or 
standardized. As such, we abstracted evaluation questions from the literature to guide reflection 
on the verification (i.e., did we build it right?) and validation (i.e., did we build the right thing?) 
of the proposed ICO revisions. These reflection questions were used to guide negotiation with 
regular meetings with ICO team members and biweekly calls with members of the Ontology for 
Biobanking (OBIB) community. The list of reflective evaluation questions includes:  
Verification 
1. Are the proposed revisions adherent to OBO Foundry principles?[114]  
2. Are the proposed and revised classes consistent across the ontology’s hierarchy?[115] 
3. Are proposed classes non-redundant?[115] 
4. Does the model capture only entities within the specified scope of the ontology? [21]  
5. Is the documentation sufficiently unambiguous to enable a consistent use of the 
terminology? [21]  
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Validation 
6. Does the ontology contain the necessary and sufficient info (identified through the source 
data) to make it fit for our particular purpose? Are all entities within the scope of the 
ontology captured?[21,115] 
7. Do the domain experts agree with the ontological analysis? [21] 
3. Results 
 3.1. Analysis and Modeling 
Prior to this evaluation and its proposed revisions, ICO was comprised of 893 classes and 
95 object properties. Table 10 provides summary counts of all classes used in the informal 
modeling process, including those ICO classes that were transferable to this new domain or 
required revision, and those that should either be imported or added to extend ICO or the OBO 
suite of ontologies for representing permissions from clinical care, including those to reuse 
residual clinical biospecimens and health data. Informal modeling of permission-sentences 
abstracted from US federal regulations and clinical consent forms used fifty-two classes and 
eleven object properties already within ICO, demonstrating the appropriateness of extending ICO 
for the clinical domain rather than developing a new ontology. Six of these classes from ICO 
were used in the informal models but were flagged for recommended revision. These proposed 
revisions were always regarding either the classes’ formal definitions (i.e., position within the 
hierarchy) or human-readable definitions, which may have been ambiguous or overly specific 
with regard to use in models of permissions. Table 11 presents all terms used to express 
permissions from the source data that were already present in ICO.   
Evaluation also revealed that considerable extension of ICO is necessary to represent all 
identified permissions from the source data. Thirty classes were identified from other OBO 
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Foundry ontologies that may/should be imported into ICO. Additionally, we recommend nine 
new classes to either be added to ICO or another OBO Foundry ontology (and imported into 
ICO) in order to express all content within the included source data. Tables 12 presents all terms 
used to express permissions from the source data that were not present in ICO but were identified 
in another OBO Foundry ontology; we recommend importing these classes. Table 13 presents 
proposed or new terms necessary for expressing permissions from the source data but were not 
identified in ICO or another OBO Foundry Ontology. Appendix E contains fifteen tables, 
reporting the respective classes and relationships used for each of the fifteen permission-
sentences from clinical consent forms, and mapping classes to sentence content. 
Early in the informal modeling process, a design pattern for the context of permission-
sentences emerged. Figure 7 demonstrates this design pattern, demonstrating how the individual 
who is granting permission (‘homo sapiens’ (NCBITaxon:9606); ‘consenter role’ 
(ICO:0000086)) participates in a process of consenting (‘informed consent process’ 
(OBI:0000810)) by using a consent form which contains a permission-sentence (‘permission 
directive’ (ICO:0000244)) that prescribes some process (‘planned process’ (OBI:0000011)). It 
should be noted that this is the most simplified version of this design pattern, and there is 
significant heterogeneity and added complexity as each permission-sentence was modeled. As an 
example, the real-world person (i.e., instance) who is the consenter may also have a range of 
other important roles including being the patient themselves (‘patient role’ (OBI:0000093)) or 
the patient’s legally authorized representative (‘legal guardian role’(OMRSE:00000038)). 
Likewise, the processes that are prescribed by permission-sentences also varied widely, but most 
often included a ‘health care process’ (OGMS:0000096)) like surgery or blood product 
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administration, a ‘specimen collection process’ (OBI:0000659), or an ‘act of data sharing’ 
(ICO:0000228).  
As the permission-sentences became more complex, so too did their informal models. 
Figure 8 demonstrates this complexity, and is based on the following permission-sentence: “…I 
give permission for GeneDx to retain any remaining sample longer than 60 days after completion 
of testing and use my de-identified data for scientific and medical research purposes.” In this 
example, not only is some process prescribed, but also specifications on how the data that 
emerged from that process may be used (‘data use limitation’(DUO:0000001)) and the timeline 
by which these processes may occur (‘temporal directive’(proposed class)). Additionally, the 
flow of a given specimen becoming a residual clinical biospecimen which bears an ‘excess 
material role’(ICO:0000313) was fleshed out to ensure that all necessary classes were modeled. 
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Table 10. Summary Counts and Sources for Terms Used in Informal Modelling 
 Classes Relationships 
Present in ICO 52 11 
Recommend Import from 
OBO Foundry Ontologies 30 -- 
New Classes 9 -- 
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Table 11. Terms Present in the Informed Consent Ontology – including PURLs, Labels, Definitions, and Proposed Revisions and 
Comments – Used to Express Permissions Identified in the Source Data. 
Note: *** in the Ontology Label column denotes that the given term was identified through the review of US Federal Regulations 
via the literature. All other terms were first identified from permission-sentences from clinical consent forms. 
 
Ontology PURL Ontology Label Ontology Definition 
Recommendations and 
Comments 
Source Ontologies: Classes 
BFO:0000040 Material Entity 
An independent continuant that is spatially 
extended whose identity is independent of 
that of other entities and can be maintained 
through time.  
DUO:0000001 Data Use Limitation  
A data item that is used to indicate consent 
permissions for datasets and/or materials, 
and relates to the purposes for which 
datasets and/or material might be removed, 
stored or used.  
DUO:0000038 genetic research 
Biomedical research concerning genetics 
(i.e., the study of genes, genetic variations 
and heredity).  
DUO:0000039 
Drug Development 
Research*** 
Biomedical research concerning drug 
development.  
IAO:0000027 Data Item*** 
a data item is an information content entity 
that is intended to be a truthful statement 
about something (modulo, e.g., 
measurement precision or other systematic 
errors) and is constructed/acquired by a 
method which reliably tends to produce 
(approximately) truthful statements.  
IAO:0000030 
Information Content 
Entity 
A generically dependent continuant that is 
about some thing.  
IAO:0021006 Obligee Role*** 
A role that is either the specified output of 
an obligation generating social act or the 
concretization of a transferable obligation 
and that is realized by its bearer being the 
providing part of a process that fulfills the 
previously agreed upon requirements.  
IAO:0021300 Obligor Role*** 
A role that is either the specified output of 
an obligation generating social act or the 
concretization of a transferable obligation 
and that is realized by its bearer being the 
receiving part of a process that fulfills the 
previously agreed upon requirements.  
ICO:0000001 Informed consent form  
A document that explains all relevant 
information to assist a human being in 
understanding the expectations and 
requirements of participation in a process, 
and is an instrument in obtaining consent 
and, after having obtained consent, is a 
record that such a consent has occurred.  
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ICO:0000019 Signature Section  
A document part that is specified as a place 
to receive a signature.  
ICO:0000053 
Drug Testing 
Investigation An investigation that targets drug testing.  
ICO:0000060 
Act of storing a 
specimen  
A planned process that involves placing a 
specimen in some location in order to 
maintain possession of it.  
ICO:0000074 
authorization for 
release of confidential 
health information 
An act of authorizing that is signed by a 
patient, or his legal representative, or 
clinical study participant for the use or 
disclosure of oral, written, or electronic 
form of confidential health information 
that identifies the individual and relates to 
the medical history, diagnosis, treatment, 
or prognosis of his condition. 
This is the only child of 
'act of authorizing' 
(ICO:0000046). Consider 
deleting the parent class. 
ICO:0000079 
Institutional Review 
Board*** 
A specially constituted organization 
comprised of medical, scientific and non-
scientific members established and 
designated by an entity to ensure the 
protection of the rights, safety and well-
being of human subjects recruited to 
participate in biomedical or behavioral 
research according to the requirements 
outlined in Title 38, part 16 (same as Title 
45, part 46 and Title 21, part 56) of the 
U.S. Code of Federal Regulations. IRB 
responsibility include but not limited to the 
reviewing, approving, and providing 
continuing review of trial protocol and 
amendments and of the methods and 
material to be used in obtaining and 
documenting informed consent of the trial. 
Other equivalent committees with the same 
or similar functions are also considered to 
be IRBs.  
ICO:0000081 
Legal Guardian 
Role*** 
A role that inheres in an individual who is 
authorized under applicable State or local 
law to consent on behalf of a child or 
incapable person to general medical care 
including participation in clinical research.  
ICO:0000083 
Individually 
Identifiable Health 
Information Entity*** 
A protected health information entity 
which identifies an individual; or with 
respect to which there is a reasonable basis 
to believe the information can be used to 
identify an individual.  
ICO:0000086 Consenter Role  
A role that inheres in a patient or the legal 
guardian when he/she participates the 
consenting process.  
ICO:0000101 
Health Information 
Entity*** 
An information content entity which is 
created or received by a health care 
provider, health plan, public health 
authority, employer, life insurer, school or 
university, or health care clearinghouse;  
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and relates to the past, present, or future 
physical or mental health or condition of 
any individual, the provision of health care 
to an individual, or the past, present, or 
future payment for the provision of health 
care to an individual. 
ICO:0000103 
Protected Health 
Information Entity 
A health information entity which is 
created, received, stored, or transmitted by 
covered entities and their business 
associates in relation to the provision of 
healthcare, healthcare operations and 
payment for healthcare services.  
ICO:0000113 
Anonymized 
information content 
entity  
An information content entity that has been 
processed to prevent the identification of 
the person with whom the data are 
associated, thereby enduring in a stasis of 
anonymization.  
ICO:0000116 
Act of Using 
Participant Data 
A planned process that involves using data 
which was an output of a human being's 
participation in a study and which is about 
that human being. 
Either need to make new 
class for patient 
information or abstract 
this concept ('Act of Using 
Data' or 'Act of Using 
Human Data'). 
ICO:0000181 Secondary Use*** 
A planned process that involves a human 
biological specimen originally collected 
for the purpose of treatment or a different 
investigation.  
ICO:0000186 
Permission Temporal 
Region  
A temporal region during which some act 
is permitted.  
ICO:0000196 
Act of Informed 
Consenting 
An act of permitting that is a process part 
of some informed consent process. 
Reconcile hierarchies; 
why is “act of permitting” 
and “act of informed 
consenting” a deontic 
declaration, whereas “act 
of authorizing” is not? 
ICO:0000199 Permission Role  
A deontic role that inheres in an agent and 
which permits certain actions.  
ICO:0000218 
Act of Removing 
Identifiable 
Information  
An act of anonymization that alters an 
information content entity by removing 
information content which identifies that 
individual.  
ICO:0000222 Signature 
An information content entity that is a 
handwritten depiction of a name.  
ICO:0000228 Act of Data Sharing 
a planned process in which data possessed 
by one person or organization is shared 
with one or more other persons or 
organizations.  
ICO:0000233 Regulatory document  
A document that either prescribes actions 
or prescribes the permissions, obligations, 
restrictions, or protections relating to 
public or legal policy.  
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ICO:0000244 Permission Directive 
A directive information entity that 
prescribes a deontic role that permits some 
action.  
ICO:0000245 
Conditional 
Permission Directive  
A conditional specification that prescribes 
a permission, should some trigger 
condition obtain. 
Change text definition to 
“occur” (delete “obtain”). 
ICO:0000248 
Obligation 
Directive*** 
A directive information entity that 
prescribes an obligation that is realized a 
deontic role that is the output of a 
document act.  
ICO:0000268 
Confidentiality 
Directive*** 
A directive information entity that 
prescribes the nondisclosure of 
information.  
ICO:0000290 Waiver Document*** 
A document designed for the purpose of 
assisting in an act of waiving, and which 
contains both some description of waiver 
and some waiver directive.  
ICO:0000307 Waiver Directive*** 
A directive information entity that 
prescribes an act of waiving.  
ICO:0000311 Act of Genetic Testing  
A planned process that involves the 
investigation of some sequence of DNA.  
ICO:0000312 
Genetic testing 
directive  
A directive information entity that 
prescribes some act of genetic testing.  
ICO:0000313 Excess material role  
A role inhering in some material entity that 
is realized in an act of artifact 
modification. 
Unclear human readable 
definition. Must also 
include what about the act 
of modification results in 
the material entity being 
'excess' 
LABO:0000107 Laboratory Test  
A measurement assay that has as input a 
specimen derived from an organism and 
that aims as having as output a data item 
that is about an entity related to the 
specimen.  
NCBITaxon:9606 Homo Sapiens  
The bipedal primate mammal, Homo 
sapiens; belonging to man or mankind; 
pertaining to man or to the race of man; 
use of man as experimental subject or unit 
of analysis in research  
OBI:0000011 Planned process 
A processual entity that realizes a plan 
which is the concretization of a plan 
specification.  
OBI:0000066 Investigation 
a planned process that consists of parts: 
planning, study design execution, 
documentation and which produce 
conclusion(s).  
OBI:0000093 Patient role  
A role which inheres in a person and is 
realized by the process of being under the 
care of a physician or health care provider  
OBI:0000112 Specimen Role 
A role borne by a material entity that is 
gained during a specimen collection  
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process and that can be realized by use of 
the specimen in an investigation. 
OBI:0000202 
Investigation Agent 
Role*** 
A role borne by an entity and that is 
realized in a process that is part of an 
investigation in which an objective is 
achieved. These processes include, among 
others: planning, overseeing, funding, 
reviewing.  
OBI:0000245 Organization 
An entity that can bear roles, has members, 
and has a set of organization rules. 
Members of organizations are either 
organizations themselves or individual 
people. Members can bear specific 
organization member roles that are 
determined in the organization rules. The 
organization rules also determine how 
decisions are made on behalf of the 
organization by the organization members.  
OBI:0000659 
Specimen Collection 
Process  
A planned process with the objective of 
collecting a specimen.  
OBI:0001769 
Specimen collector 
role  
An Investigation agent role borne by a 
person or organization which is realized in 
a specimen collection process.  
OBI:0100051 Specimen 
A material entity that has the specimen 
role.  
OGMS:0000018 Laboratory Finding  
A representation of a quality of a specimen 
that is the output of a laboratory test and 
that can support an inference to an 
assertion about some quality of the patient.  
OGMS:0000090 Treatment 
A planned process whose completion is 
hypothesized by a health care provider to 
eliminate, prevent, or alleviate the signs 
and symptoms of a disorder or pathological 
process 
Incorrect hierarchy. 
Treatment should be child 
of 'Health Care Process' 
(OGMS:0000096). 
OGMS:0000090 Documenting 
A planned process in which a document is 
created or added to by including the 
specified input in it.  
Source Ontologies: Relations 
BFO:0000051 has part 
(No definition in Ontology Lookup Service 
or Ontobee)  
CommonCore 
Ontologies/ 
prescribes prescribes 
(No definition in Ontology Lookup Service 
or Ontobee)  
DUO:0000010 Is restricted to 
(No definition in Ontology Lookup Service 
or Ontobee)  
IAO:0000136 Is about 
is:about is a (currently) primitive relation 
that relates an information artifact to an 
entity.  
OBI:0000295 is:specified:input:of 
(No definition in Ontology Lookup Service 
or Ontobee)  
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OBI:0000299 has:specified:output 
(No definition in Ontology Lookup Service 
or Ontobee)  
OBI:0000293 has:specified:input 
(No definition in Ontology Lookup Service 
or Ontobee)  
OBI:0000312 is:specified:output:of 
(No definition in Ontology Lookup Service 
or Ontobee)  
RO:0000053 bearer of 
(No definition in Ontology Lookup Service 
or Ontobee)  
RO:0000056 Participates in 
(No definition in Ontology Lookup Service 
or Ontobee)  
RO:0002350 Member of  Inverse of has member  
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Table 12. Terms from OBO Foundry Ontologies (and not in ICO) – including PURLs, Labels, Definitions, and Proposed 
Revisions and Comments – Used to Express Permissions Identified in the Source Data. 
Note: *** in the Ontology Label column denotes that the given term was identified through the review of US Federal Regulations 
via the literature. All other terms were first identified from permission-sentences from clinical consent forms. 
Ontology PURL Ontology Label Ontology Definition 
Recommendations and 
Comments 
Source Ontologies: Classes 
CHMO:0002832 Material Disposal 
A planned process in which materials for 
an experiment are removed permanently 
from the laboratory. 
Delete "for an experiment" 
as clinical biospecimens can 
similarly be disposed of. 
ERO:0000333 Video 
Data containing moving pictures stored in 
digital and analog formats.  
FBbi:00000223 
Graphic 
Illustration 
(No definition in Ontology Lookup Service 
or Ontobee)  
GEO_000000400 
Government 
Organization*** 
An organization that governs the people 
living in a particular geographical region 
or aggregate of geographical regions. The 
geographical region it governs can change 
over time (such as the westward expansion 
of the United States and the addition of 
Hawaii). Note: this definition was taken 
over from "geopolitical organization".  
IAO:0000185 Photograph 
A photograph is created by projecting an 
image onto a photosensitive surface such 
as a chemically treated plate or film, CCD 
receptor, etc.  
NCIT_C142640 
Postmarketing 
Surveillance*** 
Programs to identify adverse events that 
did not appear during the drug approval 
process.  
NCIT:C13235 Fetus 
An unborn or unhatched vertebrate in the 
later stages of development showing the 
main recognizable features of the mature 
being. 
Consider importing all age 
group and at-risk population 
classes. 
NCIT:C15380 Telemedicine 
The use of telecommunications technology 
to provide, enhance, or expedite health 
care services, as by accessing off-site 
databases, linking clinics or physicians' 
offices to central hospitals, or transmitting 
x-rays or other diagnostic images for 
examination at another site.  
NCIT:C163409 Safety Monitoring 
Review of safety data to ensure safety of 
the individuals who are participating in the 
study, or to identify potential safety 
concerns for the duration of the study 
lifecycle.  
NCIT:C16423 Child 
An age group comprised of individuals 
who are not yet an adult. The specific cut-
off age will vary by purpose. 
Consider importing all age 
group and at-risk population 
classes. 
NCIT:C43960 
Health Care 
Organization 
An organization that provides healthcare 
services or that is involved in the provision 
of health care activities. Groupings or 
If fitting into OBO Foundry 
hierarchy, should be child of 
OBI's 'organization' 
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subdivisions of an organization, such as 
departments, may also be considered as 
organizations where there is a need to 
identify them. 
(OBI:0000245) and parent of 
'hospital' (OBI:0000844) 
NCIT:C64262 
Biologic Sample 
Preservation 
Procedure 
Procedures utilized to save organic 
substances from decay. Some preservation 
procedures are meant to maintain cells, 
tissues, or organisms in a viable state.  
NCIT:C95018 Use To put into action or service.  
OBI_0001305 
Genotype 
Information*** 
a genetic characteristics information that is 
about the genetic material of an organism 
and minimally includes information about 
the genetic background and can in addition 
contain information about specific alleles, 
genetic modifications, etc.  
OBI:0000145 Pathologist Role 
a worker role of being responsible for 
making the histopathology diagnoses 
associated with data from a study; this 
activity occurs outside the study timeline  
OBI:0000207 
Health Care 
Provider Role 
a worker role of providing medical care 
either within or outside the study timeline 
Revise to exclude 
requirement of within a 
study timeline 
OBI:0600003 
Performing A 
Clinical 
Assessment 
A protocol application during which a 
series of tests are made of a patient leading 
to determination of disease state, or 
condition.  
OBIB_0000039 
Blood Specimen 
on Blood Spot 
Card*** 
A blood specimen that is located on a 
blood spot card.  
OGMS:0000096 
Health Care 
Process 
A planned process with the objective to 
improve the health status of a patient that 
directly involves the treatment, diagnosis, 
or prevention of disease or injury of a 
patient 
Import 'health care process' 
and revise hierarchy within 
ICO. Treatment should be a 
child of Health Care Process. 
OGMS:0000104 
Diagnostic 
Process 
A health care process that involves the 
interpretation of a clinical picture from a 
given patient (input) and the assertion to 
the effect that the patient has a disease, 
disorder, or syndrome of a certain type, or 
none of these (output).  
OMIABIS_0000010 
Biobank 
Organization*** 
An organization bearing legal personality 
that owns or administrates a biobank.  
OMRSE_00000087 
Employer 
Role*** 
a role in human social processes that is 
realized when the bearer provides a wage 
or salary in exchange for some labor or 
services as specified by some declaration  
OMRSE_00000093 
Insurance 
Company*** 
An organization that secures a group of 
people against pecuniary loss by payment 
of a sum of money if a specified event 
occurs.  
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OMRSE_00000198 
Information 
Content Entity-
Request 
Process*** 
a communication in which some 
participant requests of some other 
participant an information content entity 
about some portion of reality  
OMRSE:00000054 Hospital Role 
A healthcare provider role that inheres in 
an organization and is realized by 
providing inpatient and outpatient care.  
OMRSE:00000056 
Hospital 
Organization 
An organization that is the bearer of a 
hospital role.  
OMRSE:00002029 Education Process 
A planned process with an active 
participant who acquires mental 
representations of information content 
entities (ICEs), which had no previous 
mental representation in the cognitive 
system, and through repeated use or 
application of these ICEs becomes the 
bearer of a new instance of some type of 
capability, and the participant was not 
previously the bearer of that instance of 
that type of capability. 
Consider SDGIO definition. 
While logically accurate, the 
OMRSE definition is not 
easily understandable to non-
BFO users. 
SWO:3000079 Audio Format 
(No definition in Ontology Lookup Service 
or Ontobee)  
VO:0000299 Company 
(No definition in Ontology Lookup Service 
or Ontobee)  
XCO:0000527 
Genetic 
Manipulation 
A condition in which the genotype or the 
gene expression of an organism or a cell 
has been modified. 
Unknown if there are other 
types of specimen 
manipulation. Further 
domain expertise should be 
sought to determine if this 
class is sufficient or if an 
additional class is needed.  
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Table 13. Proposed/New Terms Necessary to Express Permissions Identified in the Source Data. 
Note: *** in the Ontology Label column denotes that the given term was identified through the review of US Federal Regulations 
via the literature. All other terms were first identified from permission-sentences from clinical consent forms. 
Proposed Label Proposed Definition Comments and Citations 
Classes 
Act of 
Selling*** 
To give up (property) to another for something of value 
(such as money).' 
Definition of 'sell' from Merriam-
Webster.[116] 
Covered Entity 
Role*** 
A role based on the Health Insurance Portability and 
Accountability Act that inheres in individuals, 
organizations, and agencies that are also health care 
providers, health plans, or health care clearinghouse. Definition adapted from HIPAA.[117] 
Data Recipient 
Role*** 
A natural or legal person, public authority, agency or 
another body, to which the data are disclosed. 
Definition from adapted from GDPR 
Article 4(9).[118] 
Limited Data 
Set*** 
Protected health information that excludes HIPAA-
specified identifiers of the individual or of relatives, 
employers, or household members of the individual. Definition adapted from HIPAA.[117] 
Owner Role 
A role in a human social process that is that is based on 
a social act and whose bearer exercises exclusive 
control over a property, where this control is permitted 
by one or more deontic roles, which are parts of the 
ownership role. 
After deliberation with members of the 
Document Acts Ontology, this term 
was added under PURL IAO:0020027 
by Dr. Mathias Brochhausen 
Owner Role 
Directive 
A directive information entity that prescribes the owner 
role.  
Ownership 
Process 
The process of exercising exclusive control over a 
property.  
Prospective Data 
Collection*** 
A study design in which the documentation of the 
presence or absence of an exposure of interest is 
documented at a time period preceding the onset of the 
condition being studied. 
Definition from Sage Research 
Methods.[119] 
Residual Clinical 
Biospecimen 
A material entity, collected during some health care 
process, that bears both a specimen role and an excess 
material role following some act of artifact 
modification. 
Consider also including mention that 
these specimens have fulfilled their 
clinical purpose or indication, and that 
they would otherwise be discarded. 
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Figure 7. Context for a Permission Directive (Permission-Sentence) 
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Figure 8. Informal Model for the following permission sentence: “…I give permission for GeneDx to retain any remaining 
sample longer than 60 days after completion of testing and use my de-identified data for scientific and medical research 
purposes.” 
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 3.2. Reflection and Negotiation 
At this time, all of the sampled source data from US Federal Regulations and clinical 
consent forms have been modeled and reviewed with team members. We asked the following 
evaluation questions to evaluate the proposed revisions and extensions of ICO in terms of 
verification and validation, and to determine next steps:  
  3.2.1. Verification 
1. Are the proposed revisions adherent to OBO Foundry principles?[114]  
OBO Foundry principles are centered on openness and reusability to a range of users, and 
facilitating reuse through shared best practices such as common formats, clear definitions, 
community collaborations, and regular maintenance of the ontologies.[114] ICO is released 
under a Creative Commons 3.0 license and written in web ontology language (OWL). All 
additional principles have been meet under previous evaluation efforts.[21; manuscript in 
progress] The proposed revisions from this evaluation do not affect ICO’s adherence to OBO 
Foundry principles, and any added classes will follow the naming, defining, and documentation 
requirements. 
2. Are the proposed and revised classes consistent across the ontology’s 
hierarchy?[115] 
We have made every effort to appropriately map new classes at the same level of 
granularity as similar classes across the ontology. Three of the seven proposed revisions to 
existing ICO classes revolved around editing the location within the class hierarchy, i.e., their 
formal definitions.  
3. Are proposed classes non-redundant?[115] 
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During the informal modeling phase, we attempted to use existing ICO classes wherever 
possible prior to suggesting extension of the ontology by adding classes. Likewise, we also 
searched Ontobee, a web-based tool for viewing the OBO Foundry suite of ontologies, to 
identify classes and their definitions (formal and textual) that could be imported into ICO. The 
shared logical structure and hierarchy of classes in the OBO Foundry facilitates interoperability 
and ease of importing individual classes or entire branches of the ontologies’ trees. 
4. Does the model capture only entities within the specified scope of the ontology? [21]  
Permissions from the source data and their relevant entities largely included terms 
specific to consent processes, their forms, and the individuals involved in the consent process; 
however, they also included entities that are relevant outside of consent processes, including 
health care processes such as surgeries, organizations such hospitals or biorepositories, and 
processes like the act of selling some material (e.g., biospecimen). For this reason, we plan to 
continue to negotiate all newly proposed classes both with the ICO development team and 
representatives from a range of OBO Foundry ontologies to determine where they fit best. As an 
example, efforts have already been completed to add and define the term ‘owner role’ in The 
Document Acts Ontology (D-Acts), which shares a namespace with the Information Artifacts 
Ontology (IAO). Even though ownership was a necessary concept identified through our analysis 
of the source data, the concept of ownership extends beyond the context of informed consent, for 
example including deeds and land ownership so merits modeling in an ontology that provides 
content inherited by ‘downstream’ ontologies such as ICO. 
5. Is the documentation sufficiently unambiguous to enable a consistent use of the 
terminology? [21] 
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Text definitions for all newly added terms will be entered into the ontology. Additionally, 
these text definitions will be double checked to ensure that they match the terms’ formal 
definitions.  
  3.2.2. Validation 
1. Does the ontology contain the necessary and sufficient info (identified through the 
source data) to make it fit for our particular purpose? Are all entities within the 
scope of the ontology captured? [21,115] 
As a reminder, our purpose was to represent permissions relevant to clinical care 
contexts, including reuse of residual clinical biospecimens and health data for secondary 
purposes. By systematically extracting entities from all relevant US Federal regulations and a 
sample of permission-sentences from clinical consent forms, we aimed to represent all necessary 
and sufficient classes for our purposes in ICO. After modeling a few permission-sentences, a 
distinct and consistent design pattern emerged for representing permission-sentences (this design 
pattern is previously provided in Figure 7). It should also be noted that by following our 
progression of modeling permission-sentences – from those purposively sampled for our most 
narrow use case, then purposively selected for heterogenous clinical permissions, and lastly a 
random sample of permission-sentences – we achieved saturation when identifying new classes, 
which demonstrates that a sufficient and representative sample of permission-sentences were 
modeled to capture most relevant classes. 
2. Do the domain experts agree with the ontological analysis?[21]  
We had multiple discussions ICO development team and OBIB community which 
informed iterative improvements to our preliminary informal models. We believe that we have 
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achieved a degree of stability in these revisions based on expert feedback, and that proposed 
classes can now be pushed forward to their respective ontological communities.  
4. Discussion 
This evaluation revealed substantial overlap and therefore appropriateness of using ICO 
to represent permissions in clinical care, with a focus on reusing residual clinical biospecimens 
and health data. It further identified gaps and inconsistencies in ICO for representing such 
permissions, and proposes a series of recommendations for extension and revision of ICO and 
surrounding OBO Foundry ontologies. In their study to identify the minimum metadata 
necessary for biobank information systems to share their samples and data, Norlin et al. 
recognized the need for ontologies which represent the “ethical standards under which the 
samples are collected, any restrictions on research use, and access requirements to the samples to 
expressing the permissions for reuse.”[19] Once revised, ICO will serve as a valuable 
information resource for consent information that can be referenced by systems which manage 
patients’ residual clinical biospecimens and health data, in addition to those biospecimens and 
data captured from research studies. 
This evaluation also demonstrates the value of developing and extending ontologies and 
other information resources based on a “bottom-up” modelling approach. Without use of real-
world source data (regulations and consent forms), it is unlikely that the extent of the gaps in 
ICO and other BFO-based, OBO Foundry ontologies would have been identified.  
Importantly, our evaluation and modeling process provides a roadmap for improving and 
expanding domain knowledge within ontologies, and addressing knowledge-representation gaps 
that hinder their successful uptake.[121] This role is particularly well-suited to clinical research 
informaticists, an emerging and recognized specialty that leverages informatics to discover and 
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manage new knowledge relating to health and disease and their use in research.[122] We also 
wish to amplify the need for collaboration and transparency in ontology development. There are 
hundreds to thousands of ontologies across repositories, but these ontologies are not necessarily 
interoperable. It is only with a shared semantic structure and collaborative negotiation of 
ontology structures that dynamic and changing knowledge can successfully be modeled in 
interoperable families of ontologies. This work must occur in open and collaborative 
communities to achieve transparency in knowledge representation. 
Several limitations of this evaluation are recognized. First, we reviewed informal models 
and design patterns with ICO developers and collaborators from the OBIB community, but have 
not yet formally modelled the proposed classes and their relations according to the BFO 
hierarchy, or determined with the OBO Foundry which ontologies should be the home for each 
proposed term. Upon formal modeling, reasoners will be applied to the extended version of ICO 
and other OBO Foundry ontologies to test inferencing of the new classes. Second, while we have 
worked with ontologists and clinical research informaticists, we have not yet presented our 
models to domain experts from the legal and compliance, health information management, or 
biobanking domains. However, we believe that the extensive literature review and systematic 
collection and analysis of clinical consent forms mitigates this limitation; the literature and 
approved consent forms are a form of the collective voice of domain experts. Future refinements 
will include further checking with experts to ensure we have correctly interpreted the literature 
and the permissions. 
5. Conclusion 
Representing permissions to reuse residual clinical biospecimens and health data in an 
information resource that is interoperable within a family of recognized biomedical ontologies is 
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valuable for facilitating the responsible reuse of these resources at scale. By evaluating and 
proposing revisions and extension to ICO, we make a meaningful step in this direction. Our 
methods demonstrate the use of a bottom-up approach to modeling content from their respective 
domains’ perspectives. We propose such methods as a valuable way for clinical research 
informaticists and domain experts to engage in the development and revision of semantic 
information resources.
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Chapter 5 Conclusion 
1. Introduction 
When patients receive health care services, many clinical procedures involve the 
collection of blood or tissues (i.e., biospecimens) for some assessment, diagnostic, or therapeutic 
purpose. These biospecimens may be discarded once their clinical indication is complete, but the 
reality is that many end up in biorepositories.[123] When patients commonly sign consent 
documents indicating permission for clinical procedures, these clinical consent forms also often 
include statements which grant permission to reuse whatever leftover portions of their 
biospecimens remain (i.e., residual clinical biospecimens and health data) for secondary 
purposes, including but not limited to research, education, and commercial uses.[101]  
The recognized value of these residual clinical biospecimens and associated data is 
rapidly increasing as methods for analyzing and aggregating these data advance. As an example, 
for precision health care to be actualized at the point of care, electronic health records and 
clinical decision support tools will require both genetic and health information to classify and 
identify persons according to their genotype (i.e., sequence of genetic code) and phenotype (i.e., 
classification into subpopulations based on variation in response or susceptibility to certain 
treatments or diseases).[9,124] While this type of treatment for medical conditions is yet to be 
performed on a broad scale, analyses of genomic information alongside health data have yielded 
more than 10,000 confirmed genotype-phenotype associations between 2014 and 2017.[125] 
As custodians of biospecimens and heath data, biorepositories are responsible for 
safeguarding the interests of and the information about biospecimen donors. Biorepositories and 
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researchers must ensure that biospecimens are shared in a manner that is consistent with the 
permissions granted through regulations and by biospecimen donors during the informed consent 
process under which the biospecimens were obtained.[126] However, information about the 
permissions is often only available through the time-intensive process of manually retrieving and 
reviewing informed consent forms or when this information is “locked” in local information 
management systems.[13,72] Even when information about consent is contained within 
information systems, international best practices only recommend data elements such as form 
version identifiers, relevant dates, consent method (e.g., written or verbal), consent status (e.g., 
whether or not consent was provided and/or withdrawn), and identifiers for the person from 
whom consent was obtained.[127] Permissions for biospecimen and data use are generally not 
fully represented in such systems. 
Although humans may read regulatory and consent documents and intuitively gain 
understanding of their meaning (i.e., semantics) based on contextual clues, they lack the speed 
and cognitive processing to retain and process large quantities of information at scale and the 
ability to understand information when context is lacking.[102] Computers, on the other hand, 
are powerful machines capable of great speed and processing, but on their own lack any reliable 
way to “understand” semantics.[102,128] How knowledge is classified (or organized) and 
expressed in technologies can enable or constrain discovery of that knowledge.[129,130] 
The growing demand to increase the availability of biospecimens and data must be 
considered in light of ethical imperatives to responsibly use these highly sensitive information 
resources by adhering to the permissions granted by the biospecimen donors and the rules and 
regulations which govern those biospecimens. Identification and management of information 
about informed consent and relevant regulations must be ‘known’ to all individuals and digital 
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systems that interact with the repositories in which the specimen and data are stored as well as 
the repositories that receive shared biospecimens and data. In addition to potential misuse of 
specimens and data, without such information management it is possible (if not likely) that 
banked biospecimens may be under-utilized because the determination of shareability is not 
discoverable, and/or shared without traceability of these permissions. 
Ontologies, or semantic web technologies, show great promise for representing such a 
complex field in a machine-interpretable manner. The term ontology, designated by philosophers 
as the study of the nature of existence,[131] has been adopted by information and web 
professionals to denote files which formally specify classes of entities and relationships between 
them.[17] Ontology files specify the rules of inference and inheritance, which enable computers 
to extract the contextual meaning (i.e., the semantic aspect of the semantic web) of terms and 
manipulate that information in ways similar to those of human users.[128] These technologies 
use machine-readable syntax to capture, process, and communicate meaning and knowledge 
surrounding entities and inter-entity relationships in the real world.[132] By embedding 
semantics in technologies, classification and organization of knowledge are enabled “in a 
definite and meaningful way.”[133] Likewise, when semantics are encoded into web content, 
that information becomes actionable by computers in a way that is different from syntactically-
identical sources, such as is printed in a book.[128,134] 
Ontologies also address another challenge faced by computers: the need for an 
infrastructure which enables interoperability, or the integration and circulation of potentially 
diverse data across diverse contexts with minimal effort.[102,130] For example, interoperability 
is necessary for continuous aggregation and integration of health data through linking to 
databases operated independently from the biorepositories.[127] While the challenge of 
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interoperability can in-part be addressed using machine-readable languages and standards, 
“languages and standards are of no consequence without uptake, and uptake requires increasing 
the amount of data exposed in RDF.”[134] The Resource Description Framework (RDF) is 
language for writing ontologies that encodes meaning about entities by encoding it as sets of 
three (called triples), much like the subject, predicate, and object of a sentence.[128] These 
subjects and objects become nodes of the semantic web, and the predicates (i.e., relationship 
statements) serve as the connections which link these nodes.[132] Through this common format 
and “understanding of terms, scientific data and findings [can] be consistently annotated thus 
promoting data integration and exchange across heterogeneous representations.” [104] 
In addition to the structure and language of ontologies, it is tremendously valuable that 
semantic technologies for knowledge discovery integration be developed and maintained within 
open communities for the vision of interoperability to be achieved. “Creating bespoke [software,] 
in all computer languages, for all data-types and all analytical tools that require those data-types, 
is not a sustainable activity.”[102] To address this need, development of broadly useful and 
interoperable ontologies benefit when built to fit within a network of interoperable knowledge 
representations by an open community. 
One such open community is the Open Biological and Biomedical Ontologies (OBO) 
Foundry, a collaborative dedicated to building and maintaining ontologies for the life 
sciences.[18] All OBO Foundry ontologies are realism-based and reference the shared logical 
structure of the Basic Formal Ontology (BFO). Realism-based ontologies often initiated through 
a “top-down” approach, in which “development process [start] with the definition of the most 
general concepts in the domain and subsequent specialization of the concepts.”[17] To achieve 
the aim of realism-based ontologies to classify entities and knowledge about those entities in 
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such a way that real-world instances can be described, further classification and development is 
required to embed domain expertise in ontologies at the application level.[104,135] Doing so 
“[encapsulates] the knowledge of the world that is associated with the general terms used by 
scientists in the corresponding domain.”[136] 
However, top-down approaches to modeling may contribute to gaps in knowledge 
representation that do not reflect users’ needs at the local level. It has previously been 
demonstrated that using a bottom-up approach can be used to identify these gaps and extend or 
expand information resources for interoperability.[20] Such a bottom-up approach leverages 
real-world instances and data sources and applies a data driven approach to systematically 
identify content that must be represented in an information resource, and evaluate the coverage 
of that resource for the source data’s domain. 
This dissertation employs a bottom-up modeling approach to first explore the necessary 
information regarding permissions to reuse residual clinical biospecimens and health data, 
informally model this information, and evaluate its representation within the Informed Consent 
Ontology (ICO). The following sections of this chapter summarize the results from each of the 
dissertation studies, discusses the significance of this work and related initiatives for computably 
representing consent or permissions, and concludes with envisioned next steps and future work. 
2. Summary of Chapter 2 
 Chapter 2 of this dissertation reported on a scoping review of the literature, which served 
as one source of data towards our bottom-up modelling approach. The purposes of this scoping 
review were threefold:  
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1. To identify relevant federal regulations and norms (e.g., best practices, guidance 
documents) that bear authority or give guidance over reuse of residual clinical 
biospecimens and health data in the US. 
2. To gather domain experts’ interpretations of the permissions by which such reuse 
may occur. 
3. To gather domain experts’ interpretations of the key issues and concepts – including 
the overlap, congruency, and gaps – that must be considered when interpreting these 
regulations and norms. 
Upon querying six biomedical, legal, and health policy databases; screening manuscripts; and 
reviewing full text articles, twenty-five manuscripts were included in the final review. These 
twenty-five manuscripts covered eleven US federal regulations and fifteen norms that bear 
authority or guide reuse of residual clinical biospecimens in the US.  
We found considerable inconsistencies in permissions across a patchwork of regulations 
of norms that make it difficult to tell which apply to a given use, or if the applicable regulations 
or norms even agree with each other. Further, even once the applicability of these rules is 
determined, there is considerable administrative and logistical burden for tracing such decisions 
over time, physical location, and across jurisdiction.[35,52,65] The responsible conduct of 
research is challenging given the complexity of navigating these regulations and norms, and the 
burden of humans’ interpretation of these permissions on a case-by-case basis. As such, there is 
growing need for tools to “flag” residual clinical biospecimens and health data as usable or 
unusable for a range of given activities at scale. These findings support the need for information 
regarding permission to reuse residual clinical biospecimens and health data to be represented in 
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standardized, computable, and interoperable formats. Moreover, this work provides the necessary 
information for such information systems. 
3. Summary of Chapter 3 
The second source of source data for our bottom-up modelling approach was produced 
through the annotation study reported in Chapter 3. The purpose of this study was to develop and 
test an annotation scheme for identifying permissions within clinical consent forms. This was a 
retrospective study of clinical consent forms, examining forms collected using two methods: 
direct contribution by healthcare facilities and systematic web searching. We followed 
Pustejovsky and colleagues’ MAMA (Model-Annotate-Model-Annotate) cycle as the method for 
developing and refining our annotation scheme.[80] We proposed an initial set of instructions for 
annotations, and then iteratively tested those instructions using a small subset of the data and 
revised the annotation scheme accordingly. We determined inter-annotator agreement using 
multiple methods: raw or observed agreement, Cohen’s 𝜅𝜅, weighted 𝜅𝜅 (𝜅𝜅𝑤𝑤), and Krippendorff’s 
α. 
The final annotation scheme demonstrated moderate to substantial inter-rater reliability 
with three annotators identifying permission-sentences. Of note, we did not find any other 
approaches or projects in the literature to annotate permission-sentences. While the performance 
of this annotation scheme may in-part be due to its quality or sufficiency, we believe that these 
findings may point to the complexity of identifying permission-sentences within the forms, 
which aligns with a significant body of literature which speaks to clinical consent forms being 
convoluted and incomprehensible.[99] This is ethically problematic as the nature of informed 
consent requires that information provided in consent processes and documentation be 
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understandable by consenters (e.g., clinicians) and consentees (e.g., health care consumers) 
alike.[90]  
To mitigate the amount of disagreement around identifying permission-sentences, only 
those sentences annotated by all three annotators (n= 211) were eligible as source data for the 
final ontology evaluation. Should permission-sentences ever serve as training data to 
automatically identify permission-sentences in new samples of consent forms, further 
enhancement of the annotation output must occur through careful selection of which sentences 
should or should not be included as training data.[97] These sentences might also be used to 
evaluate the coverage of ICO to verify or extend the coverage of ICO, should such analysis 
reveal that this set of sentences is qualitatively different from the 211 agreed-upon sentences.  
Use of permission-sentences identified through real-world consent forms to extend ICO 
lays an important foundation for machine-interpretation of permission information in clinical and 
clinical research information systems. It also contributes to scientific discovery by increasing the 
accessibility of materials and information resources that are permitted to be shared and 
protecting patients by honoring their agency and decision-making around complex issues.  
4. Summary of Chapter 4 
Lastly, Chapter 4 reports on our evaluation of the Informed Consent Ontology. The 
purpose of this evaluation study was to apply a hybrid model of ontology evaluation, with focus 
on evaluating ICO for its completeness in expressing permissions from regulations and clinical 
consent forms, particularly for reuse of residual clinical biospecimens and health data. We also 
aimed to develop recommendations for extension and revision based on these findings. We 
followed a formative evaluation design, adapting Friedman and Wyatt’s multistep evaluation 
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process to iteratively examine and check our findings, and integrated steps recommended in the 
ontology evaluation literature.  
We found considerable overlap of classes and object properties between ICO as presently 
published and the necessary content identified through federal regulations and clinical informed 
consent forms from the previous two studies. This overlap demonstrates the appropriateness of 
extending ICO for the clinical domain rather than developing a new ontology outright. However, 
we also found that considerable extension – either in the ICO namespace or another OBO 
Foundry ontology – is necessary to represent permissions from clinical consent, with a focus on 
reuse of residual clinical biospecimens and health data. We propose two foundational domain 
patterns based on our informal modeling step – one of the context of a permission-sentence and 
one demonstrating all classes involved when a patient permits reuse of their deidentified residual 
clinical biospecimens and health data.  
Our evaluation using questions in the literature demonstrates that, while we have already 
initiated collaborations to vet and extend the ICO and other OBO Foundry ontologies, these 
collaborations must be continued and ongoing. Once extended and revised, ICO will serve as a 
valuable information resource for consent information that can be referenced by systems which 
manage patients’ residual clinical biospecimens and health data, in addition to those 
biospecimens and data captured from research studies. 
5. Significance 
This work addresses a critical gap in formally representing the permissions of how 
residual clinical biospecimens and health data can be responsibly reused. which is of increasing 
value in data-intensive health sciences (e.g., population health, translational science, precision 
health, etc.) which require access to such information. It also adds this missing content to the 
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BFO-based biobanking suite of ontologies, enabling use alongside widely-adopted biomedical 
ontologies and acting as a valuable contribution for biobank information management. This work 
produces a machine-readable semantic resource, grounded in real-world sources included regulations 
and clinical consent forms.  
It is our hope that deployment of ICO will facilitate responsible reuse of residual clinical 
biospecimens and health data, both increasing their discoverability by entities that will advance 
scientific knowledge related to health and also protecting the agency and rights of patients, whose 
expressed choices regarding the disposition of their biospecimens and health data should be 
respected. Revising and extending ICO to this new domain enables future logical inferencing about 
permissions and obligations for sharing and use which can be adopted by a range of systems and 
applications. As examples, ICO may also be used for assessing informed consent tools such as 
eConsent forms and as a resource for mapping and annotating text in future natural language 
processing tasks. It may also be used to build query tools or decision support systems to support 
covered entities, biorepositories, federated research networks, institutional review boards, and 
other individuals in identifying eligible biospecimen and data resources that meet their needs or 
deciding if and when certain biospecimen and data resources should be shared.  
Another strength and important feature of this work is the demonstration of a bottom-up 
modeling approach to evaluate and extend an existing information resource using real-world 
source data. We suggest that this approach may demonstrate a clear entry point for domain experts 
to interact with the ontology development community, to be involved in formal modeling efforts, 
and to develop ontologies that meet the needs of their communities both broadly and at the local 
levels.  
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6. Related Efforts 
In addition to ICO, there are a number of initiatives related to computable representations 
of consent and permissions presented throughout the literature. Nearly a decade ago, two 
permissions ontologies emerged in the literature, both for representing permissions granted 
during research consent processes. Obeid and Sanderson introduced the Biomedical Research 
Permissions Ontology as a part of Health Sciences South Carolina’s (HSSC) initiative to provide 
a “comprehensive mechanism for managing informed consents and other research 
permissions.”[137] Grando and Schwab likewise introduced their permissions ontology, 
designed and tested using actual investigator queries and study participants’ data to determine 
reasoners’ conformance to the permissions granted by those study participants in consent 
forms.[72] Each of these efforts focused on consent permissions granted by research participants 
of IRB-regulated studies, not for reuse of residual clinical biospecimens. Furthermore, despite 
initial publication of efforts, it does not appear that either of these ontologies are actively 
maintained or made publicly accessible online.  
Others have addressed the need for common terminology in the context of biobanks, 
including a common language of informed consent.[138] However, the ontology development 
efforts that sought to express such language as an ontology, the Ontologized Minimum 
Information about Biobank Data Sharing (OMIABIS), stops just short of representing informed 
consent. In recent years, collaborations have occurred between members of the ICO and 
OMIABIS development communities to sufficiently represent consent processes in the context of 
biobanking.[139] Lastly, the Data Use Ontology (DUO) is now adopted by the Global Alliance 
for Genomics & Health (GA4GH) as standard coded data elements for describing data use 
 104 
categories at the data set level, but not the level of permission-sentences within a consent 
document.[140] 
However, ontologies are not the only format for facilitating biomedical information 
exchange. HL7 is a family of standards for the facilitation of health information exchange, many 
of which automate data sharing and underlie systems for providing patient care. One standard, 
the Fast Healthcare Interoperability Resources (FHIR) Specification “aims to simplify 
implementation without sacrificing information integrity.”[141,142] FHIR’s most recent release 
includes an in-trial representation of consent, the development of which is currently in-progress 
by FHIR’s Community Based Collaborative Care Work Group.[143] Data elements include a 
diverse range of patient, policy, and data information. The scope of FHIR’s representation of 
consent targets four uses: (a) privacy, to collect, access, use or share information; (b) medical 
treatment, to undergo treatment; (c) research, to participate in research; and (d) advance care 
directives. However, only the privacy directive is modeled at this time.  
This dissertation work builds on the Informed Consent Ontology. Like the 
aforementioned permissions ontology efforts, ICO was developed to represent permissions 
within research consents. In this set of studies, we used a bottom-up approach to identify detailed 
content and language related to permissions in clinical consent processes, with a focus on when 
patients are asked for permission to reuse their residual clinical biospecimens and health data for 
secondary purposes. We completed an in-depth review of the literature as well as clinical consent 
documents to identify key entities and relationships. Leveraging design patterns from ICO and 
other ontologies, we demonstrated a way forward for inclusion of permissions related to clinical 
consents within ICO. In this way, we provide a uniformly modeled framework for addressing 
consent permissions, whether they arise from research or clinical consents. 
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7. Next Steps 
Going forward, we anticipate several next steps that will be essential if ICO is to be 
adopted. First, we envision development of a permissions ontology that directly integrates with 
the extended ICO. This ontology requires modeling the semantic structure of a permission-
sentence, and all the variability that may occur across permission-sentences. This effort is 
presently underway, and is likely to be particularly useful in the identification and parsing of 
permission-sentences in natural language processing tasks. 
Second, we envision and are making efforts towards collaborating with key standards 
groups, aiming for integration and interoperability among our efforts. Towards this aim, we 
believe ICO could be an asset to Ga4GH efforts. Ga4GH already uses DUO, which is 
interoperable with ICO based on the shared BFO hierarchy and compliance with OBO Foundry 
principles. In addition to data use codes at the data set level (a limitation of DUO), ICO can 
support the need for granular expressions of permissions within consent forms.  
Third, we hope to participate in further iterations and extensions of FHIR/HL7’s Security 
and Privacy Ontology and Consent Resource. This initiative is rapidly gaining increased and 
national attention. In 2019, “the ONC Cures Act Notice of Proposed Rulemaking (NPRM) 5 was 
released, which intends to advance and support seamless and secure access to, exchange of, and 
use of [electronic health information], particularly through apps.”[144] While it is envisioned 
that patients and healthcare consumers will manage their health information, it is likewise 
expected that there will be increasing demand for computable and interoperable representations 
of consent and permissions within these applications. The FHIR consent resource is currently a 
focus of major development efforts to enable interoperability; however, as previously mentioned, 
only the privacy use case is modeled. Additional work is needed to test and refine this resource, 
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in addition to developing the Medical Treatment Consent Directive, Research Consent Directive, 
and Advanced Care directive resources. There is demand for these resources, and we believe our 
perspective and foundation in disentangling clinical consent and permissions makes us suitable 
candidates to contribute to such efforts. 
In summary, the work presented in this dissertation provides an essential and previously 
missing foundation for representing informed consent and permissions related to reuse of 
residual biospecimens and health data. We envision that patients will not only have agency over 
what happens to them, their bodies, biospecimens, and data, but also that these permissions will 
be traceable and interpretable over time and across systems which reference these permissions. 
In this way, our work may contribute to protecting patients. While such applications do not yet 
exist, extension of ICO for clinical permissions is an initial and foundational step towards this 
vision. 
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Appendices  
 
Appendix A: Complete Search Strategy including Search Terms and Results by Database 
 PubMed NexisUni HeinOnline 
Health Policy 
Reference 
Center 
Philosopher’s 
Index 
Public Affairs 
Index 
 
AND 
specimen OR specimens OR biospecimen* 
OR "Specimen Handling"[Mesh] specimen OR specimens OR biospecimen* specimen OR specimens OR biospecimen* 
sharing OR share* OR releas* OR distribut* sharing OR share* OR releas* OR distribut* -- 
permission OR permissions OR consent OR 
consents 
permission OR permissions OR consent OR 
consents 
permission OR permissions OR consent OR 
consents) 
-- 
HIPAA OR “Health Insurance Portability and 
Accountability Act” OR "FDA" OR "Food and 
Drug Administration" 
-- 
Filters 1997-present; English only 
1997-present; US 
Federal Jurisdiction, 
Category: Law Reviews 
and Journals 
1997-present; Law Journal Library and 
(Location) United States of America, United 
States 
1997-present; English only 
Results 345 247 332 183 32 28 
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Appendix B: Facilities in Sample of Clinical Consent Forms 
Table 14. List and Descriptions of All Facilities in Sample of Clinical Consent Forms 
Facility Name City State Ownership 
Search 
Strategy 
Form 
Count 
Acute Care Hospitals  
Bon Secours St Mary’s Hospital Richmond VA NFP - Church RAND 2 
Boston Medical Center Boston MA NFP - Private CTSA 1 
Cape Fear Valley Health Hoke Hospital Raeford NC NFP - Private RAND 1 
Columbia University Irving Medical Center New York NY NFP - Private CTSA 1 
Doctors' Community Hospital Lanham MD Proprietary RAND 1 
Emory Healthcare Atlanta GA NFP - Private CTSA 1 
GHS Laurens County Memorial Hospital Clinton SC NFP - Private RAND 1 
Hospital of The University of Pennsylvania Philadelphia PA NFP - Private CTSA 1 
Indiana University Health Indianapolis IN NFP - Private 
CTSA, 
RAND 
3 
Indiana University Health Arnett Hospital Lafayette IN NFP - Private 
 
RAND 
1 
Intermountain Medical Center Murray UT NFP - Private RAND 3 
Johns Hopkins Health System Baltimore MD NFP - Private CTSA 1 
Karmanos Cancer Center Detroit MI Proprietary MHIMA 1 
Mayo Clinic Hlth System Franciscan Med 
Ctr La Crosse WI NFP - Private RAND 
1 
Mayo Clinic Rochester Rochester MN NFP - Church 
CTSA, 
RAND 
1 
Mclaren Oakland Pontiac MI NFP - Private MHIMA 1 
Montefiore Medical Center Bronx NY NFP - Other CTSA 1 
Mount Carmel New Albany Surgical 
Hospital New Albany OH Proprietary RAND 
1 
Mount St Mary's Hospital and Health Center Lewiston NY NFP - Church RAND 1 
MUSC Medical Center of Medical 
University of South Carolina Charleston SC Govt. - State CTSA 
1 
North Austin Medical Center Austin TX Proprietary RAND 2 
Northwestern Memorial Hospital Chicago IL NFP - Private CTSA 2 
OHSU Hospital Portland OR Govt. - State CTSA 5 
Piedmont Athens Regional Medical Center Athens GA NFP - Other RAND 1 
Piedmont Rockdale Hospital Conyers GA Proprietary RAND 1 
St Bernard’s Medical Center Jonesboro AR NFP - Private RAND 2 
St Lucie Medical Center 
Port Saint 
Lucie FL Proprietary RAND 
2 
St Luke's Des Peres Hospital Saint Louis MO Proprietary RAND 1 
St Mary Mercy Hospital Livonia MI NFP - Private MHIMA 13 
Strong Memorial Hospital Rochester NY NFP - Private 
CTSA, 
RAND 
16 
SUNY Downstate Medical Center University 
Hospital Brooklyn NY NFP - Private CTSA 
1 
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ThedaCare Regional Medical Center - 
Neenah Inc Neenah WI NFP - Private RAND 
1 
UC Health Cincinnati OH NFP - Private CTSA 1 
UC San Diego Health Hillcrest - Hillcrest 
Med Ctr San Diego CA NFP - Other CTSA 
1 
UF Health Shands Hospital Gainesville FL NFP - Private CTSA 1 
Facility Name City State Ownership 
Search 
Strategy 
Form 
Count 
UNC Health Care System Chapel Hill NC NFP - Private CTSA 3 
University of California Davis Medical 
Center Sacramento CA NFP - Other CTSA 
2 
University of Iowa Hospitals and Clinics Iowa City IA NFP - Private CTSA 3 
University of Kansas Hospital Kansas City KS 
Govt. - Hospital 
District or 
Authority CTSA 
1 
University of Kentucky Albert B. Chandler 
Hospital Lexington KY Govt. - State CTSA 
1 
University of Miami Health System Miami FL NFP - Private CTSA 1 
University of Michigan Health System Ann Arbor MI NFP - Private 
CTSA, 
MHIMA, 
RAND 
16 
University Of New Mexico Hospitals Albuquerque NM Govt. - State CTSA 1 
UPMC Pittsburgh PA NFP - Private CTSA 1 
UT Southwestern University Hospital-Zale 
Lipshy Dallas TX Govt. - State CTSA 
1 
VCU Medical Center Richmond VA 
Govt. - Hospital 
District or 
Authority CTSA 
2 
Wellstar Cobb Hospital Austell GA NFP - Other RAND 3 
Yale-New Haven Health System New Haven CT NFP - Private CTSA 1 
Children's Hospitals  
Children's National Health System Washington DC NFP - Private CTSA 1 
Critical Access Hospitals  
CHI St Alexius Health Williston Williston ND NFP - Church RAND 2 
Christus Mother Frances Hospital- 
Winnsboro Winnsboro TX NFP - Private RAND 
2 
Pinckneyville Community Hospital Pinckneyville IL 
Govt. - Hospital 
District or 
Authority RAND 
1 
UHHS Memorial Hospital of Geneva Geneva OH NFP - Private RAND 1 
Psychiatric Hospitals  
Pacific Grove Hospital Riverside CA Proprietary RAND 1 
Springfield Hospital Center Sykesville MD Govt. - State RAND 1 
Windhaven Psychiatric Hospital 
Prescott 
Valley AZ NFP - Private RAND 
1 
Ambulatory Surgical Centers  
Chambersburg Endoscopy Center LLC Chambersburg PA (not specified) RAND 3 
CSA Surgical Center LLC Columbia MO (not specified) RAND 2 
Georgia Lithotripsy and Laser Center Athens GA (not specified) RAND 2 
Gwinnett Endoscopy Center Pc Lawrenceville GA (not specified) RAND 2 
Hamilton Surgical Center Inc Hamilton NJ (not specified) RAND 1 
Spivey Station Surgery Center Jonesboro GA (not specified) RAND 1 
Key: Govt. = Government; NFP = Not for Profit; RAND = Randomly Selected  
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Appendix C: Final Coding Guidelines and Procedures for Annotation 
Purpose 
The purpose of this document is to describe annotation criteria so that human annotators can 
identify permissions in the provided texts (i.e., consent forms). 
Definition 
For purposes of this project, we define a permission as statement(s) that, upon signature of 
the consent form, authorizes any new action or activity that may, must, or must not be done. 
• We are NOT interested in permissions for payment or hospital operations. Do not 
annotate these permissions. 
 
Login and Technical Instructions 
1. Navigate to DataTurks and Login 
2. On the “My Projects” page, click on the project that you intend to work on (see project 
names under each annotation round below) 
3. On the project’s dashboard, click “Start Tagging” 
4. You will be directed to eligible texts for annotation. Follow the corresponding 
instructions (below) for each annotation round. 
 
Identifying Relevant Permissions (and Confidence) 
1. Open your DataTurks Project 
2. Read the entirety of the consent form. Do not mark up any text. 
3. Read through the form again. Highlight the sentence(s) which contain permission(s), 
selecting a label corresponding with your confidence that it is a permission: 
• A: I am certain that this is a permission. 
• B: This may be a permission. 
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4. Read through the form again. Verify all annotations. 
5. Once you have completed all annotations on a text, click “Move to Done” at the bottom 
of the page (or ctrl+entr). Or, if you want to revisit a text before submitting it as done, 
click “Skip” at the bottom of the page (or ctrl+q). 
 
NOTES 
For all annotations, highlight the entire sentence(s) from the first non-whitespace character 
to the last punctuation character. 
• If there is no end punctuation, you may need to assume its presence. 
• If statements indicate free text entry, highlight to the end of the text entry space (e.g., 
line ___) if visible in the .txt file (do not highlight trailing hard returns or white space) 
There are various configurations of permissions and sentences: 
• If a sentence contains a single permission, highlight that sentence once. 
• If a sentence contains multiple permitted actions/activities, highlight the entire sentence 
once.  
• If sequential sentences contain different permissions, highlight them separately. 
Do not annotate permissions related to payment or hospital operations (e.g., insurance, 
contact) 
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Appendix D: Pairwise Agreement Measures and Corresponding Contingency Tables 
Pairwise Inter-annotator Agreement across 3 Labels (A:Is, B:MightBe, C:Not) 
 
Table 15. Inter-annotator Agreement between PI and RA across 3 Labels (A:Is, B:MightBe, C:Not) 
  PI  
  A:Is B:MightBe C:Not  
RA 
A:Is 237 18 158 413 
B:MightBe 7 3 46 56 
C:Not 89 38 5803 5930 
  333 59 6007 6399 
 
Agreement Measure 95% CI 
𝐴𝐴𝑜𝑜 0.9444 -- 
Cohen’s 𝑘𝑘 0.5606 0.5162-0.6050 
𝑘𝑘𝑤𝑤 0.5997 0.5603-0.6391 
 
Table 16. Inter-annotator Agreement between RN and RA across 3 Labels (A:Is, B:MightBe, C:Not) 
  RN  
  A:Is B:MightBe C:Not  
RA 
A:Is 268 3 142 413 
B:MightBe 7 1 48 56 
C:Not 176 25 5729 5930 
  451 29 5919 6399 
 
Agreement Measure 95% CI 
𝐴𝐴𝑜𝑜 0.9373 -- 
Cohen’s 𝑘𝑘 0.5466 0.5036-0.5896 
𝑘𝑘𝑤𝑤 0.5731 0.5342-0.6120 
 
Table 17.Inter-annotator Agreement between PI and RN across 3 Labels (A:Is, B:MightBe, C:Not) 
  PI  
  A:Is B:MightBe C:Not  
RN 
A:Is 268 17 166 451 
B:MightBe 3 1 25 29 
C:Not 62 41 5816 5919 
  333 59 6007 6399 
 
Agreement Measure 95% CI 
𝐴𝐴𝑜𝑜 0.9509 -- 
Cohen’s 𝑘𝑘 0.6165 0.5751-0.6579 
𝑘𝑘𝑤𝑤 0.6504 0.6132-0.6876 
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Pairwise Inter-annotator Agreement across 2 Labels (A=B, C:Not) 
 
Table 18. Inter-annotator Agreement between PI and RA across 2 Labels (A=B, C:Not) 
  PI  
  A=B C:Not  
RA A=B 265 204 469 
C:Not 127 5803 5930 
  392 6007 6399 
 
Agreement Measure 95% CI 
𝐴𝐴𝑜𝑜 0.9483 -- 
Cohen’s 𝑘𝑘 0.5881 0.5449-0.6313 
 
 
Table 19. Inter-annotator Agreement between RN and RA across 2 Labels (A=B, C:Not) 
  RN  
  A=B C:Not  
RA A=B 279 190 469 
C:Not 201 5729 5930 
  480 5919 6399 
 
Agreement Measure 95% CI 
𝐴𝐴𝑜𝑜 0.9389 -- 
Cohen’s 𝑘𝑘 0.5550 0.5123-0.5977 
 
 
Table 20. Inter-annotator Agreement between PI and RN across 2 Labels (A=B, C:Not) 
  PI  
  A=B C:Not  
RN A=B 289 191 480 
C:Not 103 5816 5919 
  392 6007 6399 
 
Agreement Measure 95% CI 
𝐴𝐴𝑜𝑜 0.9541 -- 
Cohen’s 𝑘𝑘 0.6385 0.5981-0.6789 
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Appendix E: Terms to Express Permission-Sentences in Clinical Consent Forms 
 
Table 21. Terms and Sentence References to Express the Permission-Sentence: “By signing this form, I am requesting and giving 
my consent for MHSM and the doctors and/or nurses to give me blood and/o blood products during this admission or series of 
treatments.” 
By signing this form, I am requesting and giving my consent for MHSM and the doctors and/or nurses to give me 
blood and/o blood products during this admission or series of treatments. 
Ontology PURL Ontology Label Sentence Reference 
Classes 
ICO:0000199 Permission Role 
'consent for MHSM and the doctors and/or 
nurses' 
OBI:0000093 Patient Role 'to give me blood' 
ICO:0000086 Consenter Role 'I am requesting' 
OBI:0000207 health care provider role  'doctors and/or nurses' 
OBI:0000245 organization 'MHSM' 
OMRSE:00000054 hospital role  'MHSM' 
OMRSE:00000056 Hospital organization  'MHSM' 
NCBITaxon:9606  Homo Sapiens  'I', 'me', 'doctors and/or nurses' 
OGMS:0000096 Health Care Process  'give me blood and/or blood products' 
OGMS:0000090 Treatment 'give me blood and/or blood products' 
ICO:0000019 Signature Section 'By signing this form' 
ICO:0000222 Signature 'By signing this form' 
ICO:0000196 act of informed consenting 'I am requesting' 
ICO:0000001 Informed consent form  'this form' 
ICO:0000244 Permission Directive entire sentence 
-- Temporal Directive 'during this admission or series of treatments' 
ICO:0000186 Permission Temporal Region  'during this admission or series of treatments' 
Relations 
BFO:0000051 has part  
BFO:0000054 Realized in  
CommonCore 
Ontologies/prescribes prescribes  
DUO:0000010 Is restricted to  
OBI:0000293 has:specified:input  
RO:0000053 bearer of  
RO:0000056 Participates in  
RO:0002350 Member of  
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Table 22. Terms and Sentence References to Express the Permission-Sentence: “Your signature below indicates that you 
understand to your satisfaction the information about the genetic testing ordered by your health care provider and that you 
consent to having this testing performed.” 
Your signature below indicates that you understand to your satisfaction the information about the genetic testing 
ordered by your health care provider and that you consent to having this testing performed. 
Ontology PURL Ontology Label Sentence Reference 
Classes 
ICO:0000199 Permission Role 
'that you consent to having this testing 
performed' 
OBI:0000093 Patient Role 
'ordered by your health care provider' and 'to 
having this testing performed' 
ICO:0000086 Consenter Role 'your signature below indicates... consent' 
OBI:0000207 Health Care Provider Role 'health care provider' 
NCBITaxon:9606 Homo Sapiens  'your', 'health care provider' 
ICO:0000019 Signature Section  'signature below' 
ICO:0000222 Signature 'signature below' 
ICO:0000196 Act of Informed Consenting 'your signature below indicates... consent' 
ICO:0000001 Informed consent form  'signature below' 
ICO:0000312 Genetic testing directive  'consent to having this testing performed' 
ICO:0000311 Act of Genetic Testing  'genetic testing' 
ICO:0000244 Permission Directive entire sentence 
Relations 
BFO:0000051 has part  
BFO:0000054 Realized in  
CommonCore 
Ontologies/prescribes prescribes  
RO:0000053 bearer of  
RO:0000056 Participates in  
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Table 23. Terms and Sentence References to Express the Permission-Sentence: “I consent to the Facility videotaping, 
photographing, video monitoring, or taking other recordings of me or parts of my body for diagnosis, treatment, research, or 
patient safety purposes.” 
I consent to the Facility videotaping, photographing, video monitoring, or taking other recordings of me or parts of 
my body for diagnosis, treatment, research, or patient safety purposes. 
Ontology PURL Ontology Label Sentence Reference 
Classes 
ICO:0000199 Permission Role 'I consent to' 
OBI:0000093 Patient Role 'for diagnosis, treatment, ..." 
ICO:0000086 Consenter Role 'I consent to' 
OBI:0000245 Organization 'the facility' 
NCBITaxon:9606  Homo Sapiens  'I' 
-- Health Care Organization  'the facility' 
OGMS:0000096 Health Care Process  'I consent to' 
ICO:0000196 act of informed consenting 'I consent to' 
ICO:0000001 Informed consent form  Implicit 
IAO:0000572 Documenting 
'videotaping, photographing, video 
monitoring, or taking other recordings' 
BFO:0000040 Material Entity 
'videotaping, photographing, video 
monitoring, or taking other recordings' 
IAO:0000030 Information Content Entity 
'videotaping, photographing, video 
monitoring, or taking other recordings' 
ERO:0000333 Video 'videotaping', 'video monitoring' 
IAO:0000185 Photograph photographing' 
ICO:0000244 Permission Directive entire sentence 
DUO:0000001 Data Use Limitation 
'for diagnosis, treatment, research, or 
patient safety purposes' 
OGMS:0000104 Diagnostic Process 'diagnosis' 
OGMS:0000090 Treatment 'treatment' 
OBI:0000066 Investigation 'research' 
NCIT:C163409 Safety Monitoring 'patient safety purposes' 
Relations 
BFO:0000051 has part  
BFO:0000054 Realized in  
CommonCore 
Ontologies/prescribes prescribes  
OBI:0000295 is:specified:input:of  
OBI:0000299 has:specified:output  
RO:0000053 bearer of  
RO:0000056 Participates in  
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Table 24. Terms and Sentence References to Express the Permission-Sentence: “I hereby consent to the use and disclosure of my 
protected health information as described in the Notice of Privacy Practices.” 
I hereby consent to the use and disclosure of my protected health information as described in the Notice of Privacy 
Practices. 
Ontology PURL Ontology Label Sentence Reference 
Classes 
ICO:0000199 Permission Role 'consent to the use and disclosure of' 
OBI:0000093 Patient Role 'I', 'my protected health information' 
ICO:0000086 Consenter Role 'I hereby consent to' 
NCBITaxon:9606  Homo Sapiens  'I', 'my' 
ICO:0000196 act of informed consenting 'I hereby consent to' 
ICO:0000001 Informed consent form  Implicit 
ICO:0000244 Permission Directive entire sentence 
ICO:0000233 Regulatory document  'Notice of Privacy Practices' 
ICO:0000116 Act of Using Participant Data 'use' 
ICO:0000228 Act of Data Sharing 'disclosure' 
ICO:0000074 
authorization for release of 
confidential health 
information 
'I hereby consent to the use and disclosure of my 
protected health information' 
ICO:0000103 
Protected Health Information 
Entity 'protected health information' 
Relations 
BFO:0000051 has part  
BFO:0000054 Realized in  
CommonCore 
Ontologies/prescribes prescribes  
IAO:0000136 Is about  
OBI:0000295 is:specified:input:of  
RO:0000053 bearer of  
RO:0000056 Participates in  
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Table 25. Terms and Sentence References to Express the Permission-Sentence: “I hereby authorize XXX to retain, preserve and 
use for scientific or teaching purposes, or to dispose at its discretion or convenience, any specimen or tissues taken from my body 
during my visit.” 
I hereby authorize XXX to retain, preserve and use for scientific or teaching purposes, or to dispose at its discretion 
or convenience, any specimen or tissues taken from my body during my visit. 
Ontology PURL Ontology Label Sentence Reference 
Classes 
ICO:0000199 Permission Role 'hereby authorize XXX' 
OBI:0000093 Patient role 'I', 'my body during my visit' 
ICO:0000086 Consenter Role 'I hereby authorize' 
OBI:0000207 health care provider role 
'taken from my body', implicit for health care 
provider who collects the specimen or tissues 
OBI:0000245 Organization 'XXX' 
OMRSE:00000054 hospital role 'XXX' 
NCBITaxon:9606 Homo Sapiens 
'I', 'my', implicit for health care provider who 
collects the specimen or tissues 
ICO:0000196 Act of Informed Consenting 'I hereby authorize' 
ICO:0000001 Informed consent form Implicit 
ICO:0000244 Permission Directive entire sentence 
OBI:0100051 Specimen 'any specimen or tissues' 
ICO:0000060 Act of storing a specimen 'to retain' 
NCIT:C64262 
Biologic Sample Preservation 
Procedure  
OBI:0000066 Investigation 'use for scientific... purposes' 
OMRSE:00002029 education process 'use for... teaching purposes' 
CHMO:0002832 Material disposal 'to dispose' 
OBI:0000659 Specimen Collection Process 'taken from my body' 
-- Temporal Directive 'during my visit' 
ICO:0000186 Permission Temporal Region  'during my visit' 
Relations 
BFO:0000051 has part  
BFO:0000054 Realized in  
CommonCore 
Ontologies/prescribes prescribes  
OBI:0000295 is:specified:input:of  
OBI:0000299 has:specified:output  
RO:0000053 bearer of  
RO:0000056 Participates in  
RO:0002350 Member of  
Note: XXX denotes a health care facility which voluntarily contributed consent form(s) for these studies. 
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Table 26. Terms and Sentence References to Express the Permission-Sentence: “I am a New York state resident and I give 
permission for GeneDx to retain any remaining sample longer than 60 days after completion of testing and use my de-identified 
data for scientific and medical research purposes.” 
I am a New York state resident and I give permission for GeneDx to retain any remaining sample longer than 60 
days after completion of testing and use my de-identified data for scientific and medical research purposes. 
Ontology PURL Ontology Label Sentence Reference 
Classes 
ICO:0000199 Permission Role 'I give permission to GeneDx' 
OBI:0000093 Patient Role 'any remaining sample', 'my deidentified data' 
ICO:0000086 Consenter Role 'I give permission' 
OBI:0000207 health care provider role  Implicit health care provider who collects the sample 
VO:0000299 Company 'GeneDx" 
NCBITaxon:9606  Homo Sapiens  'I', 'my', implicit health care provider 
OBI:0000659 Specimen Collection Process 
Implicit in process by which a clinically collected 
specimen becomes a residual clinical biospecimen 
OBI:0100051 Specimen 'sample' 
LABO:0000107 Laboratory Test 
Implicit in process by which a clinically collected 
specimen becomes a residual clinical biospecimen 
OGMS:0000018 Laboratory Finding 
Implicit in process by which a clinically collected 
specimen becomes a residual clinical biospecimen 
ICO:0000313 Excess Material Role 'remaining sample' 
-- 
Residual Clinical 
Biospecimen 'remaining sample' 
ICO:0000218 
Act of Removing Identifiable 
Information 'de-identified data' 
ICO:0000113 
Anonymized Information 
Content Entity 'de-identified data' 
ICO:0000060 Act of Storing a Specimen 'to retain any remaining sample' 
ICO:0000196 act of informed consenting 'I give permission' 
ICO:0000001 Informed consent form  Implicit 
ICO:0000244 Permission Directive Entire Sentence 
-- Temporal Directive 'give permission to... retain.. longer than 60 days' 
ICO:0000186 Permission Temporal Region  'longer than 60 days' 
Relations 
BFO:0000051 has part  
BFO:0000054 Realized in  
CommonCore 
Ontologies/prescribes prescribes  
DUO:0000010 Is restricted to  
OBI:0000293 has:specified:input  
RO:0000053 bearer of  
RO:0000056 Participates in  
RO:0002350 Member of  
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Table 27. Terms and Sentence References to Express the Permission-Sentence: “I also consent to diagnostic studies, tests, 
anesthesia, x-ray examinations and any other treatment or courses of treatment relating to the diagnosis or procedure described 
herein.” 
I also consent to diagnostic studies, tests, anesthesia, x-ray examinations and any other treatment or courses of 
treatment relating to the diagnosis or procedure described herein. 
Ontology PURL Ontology Label Sentence Reference 
Classes 
OBI:0000093 Patient Role 
'I', 'diagnostic studies, tests, anesthesia, 
x-ray examinations and any other 
treatment or courses of treatment'' 
ICO:0000086 Consenter Role 'I also consent to' 
NCBITaxon:9606  Homo Sapiens  'I' 
OGMS:0000096 Health Care Process  
'diagnostic studies, tests, anesthesia, x-
ray examinations and any other 
treatment or courses of treatment' 
ICO:0000196 act of informed consenting 'I also consent to' 
ICO:0000001 Informed consent form  Implicit 
ICO:0000245 Conditional Permission Directive 
'consent to... relating to the diagnosis 
or procedure described herein' 
Relations 
BFO:0000051 has part  
BFO:0000054 Realized in  
CommonCore 
Ontologies/prescribes prescribes  
RO:0000053 bearer of  
RO:0000056 Participates in  
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Table 28. Terms and Sentence References to Express the Permission-Sentence: “I DONATE and authorize XXX to own, use, 
retain, preserve, manipulate, analyze, or dispose of any excess tissues, specimens, or parts of organs that are removed from my 
body during the procedures described above and are not necessary for my diagnosis or treatment.” 
I DONATE and authorize XXX to own, use, retain, preserve, manipulate, analyze, or dispose of any excess tissues, 
specimens, or parts of organs that are removed from my body during the procedures described above and are not 
necessary for my diagnosis or treatment. 
Ontology PURL Ontology Label Sentence Reference 
Classes 
ICO:0000199 Permission Role 'I... authorize XXX' 
OBI:0000093 Patient role 'I', 'my diagnosis or treatment' 
ICO:0000086 Consenter Role 'I DONATE and authorize' 
OMRSE:00000056 Hospital organization 'XXX' 
NCBITaxon:9606 Homo Sapiens 'I', 'my' 
ICO:0000245 Conditional Permission Directive 
'I... authorize... and are not necessary for my 
diagnosis or treatment.' 
ICO:0000196 Act of Informed Consenting 'I DONATE and authorize' 
ICO:0000001 Informed consent form Implicit 
-- Owner role 'to own' 
-- Owner role directive 'I DONATE and authorize XXX to own' 
-- Ownership process 'to own' 
-- Residual clinical biospecimen 'excess tissues, specimens, …organs' 
OBI:0000659 Specimen Collection Process 'removed from my body' 
OBI:0100051 Specimen 'excess tissues, specimens, or parts of organs' 
LABO:0000107 Laboratory Test 
Implicit in process by which a specimen 
becomes a residual clinical biospecimen 
OGMS:0000018 Laboratory Finding 
Implicit in process by which a specimen 
becomes a residual clinical biospecimen 
ICO:0000313 Excess Material Role 'excess tissues, specimens, …organs' 
NCIT:C95018 Use 'use' 
ICO:0000060 Act of storing a specimen 'retain' 
NCIT:C64262 Biologic Sample Preservation Procedure 'preserve' 
XCO:0000527 Genetic manipulation 'manipulate' 
OBI:0000066 Investigation 'analyze' 
CHMO:0002832 Material disposal 'dispose of' 
Relations 
BFO:0000051 has part  
BFO:0000054 Realized in  
CommonCore 
Ontologies/prescribes prescribes  
OBI:0000293 has:specified:input  
OBI:0000295 is:specified:input:of  
RO:0000053 bearer of  
RO:0000056 Participates in  
Note: XXX denotes a health care facility which voluntarily contributed consent form(s) for these studies. 
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Table 29. Terms and Sentence References to Express the Permission-Sentence: “I agree that any excess tissue, fluids or 
specimens removed from my body during my outpatient visit or hospital stay ( my specimens ) that would otherwise be disposed 
of by the Hospital may be used for such educational purposes and research, including research on the genetic materials (DNA).” 
I agree that any excess tissue, fluids or specimens removed from my body during my outpatient visit or hospital 
stay ( my specimens ) that would otherwise be disposed of by the Hospital may be used for such educational 
purposes and research, including research on the genetic materials (DNA). 
Ontology PURL Ontology Label Sentence Reference 
Classes 
ICO:0000199 Permission Role 'I agree... by the hospital' 
OBI:0000093 Patient Role 'during my outpatient visit or hospital stay' 
ICO:0000086 Consenter Role 'I agree that' 
OMRSE:00000056 Hospital organization 'the hospital' 
NCBITaxon:9606  Homo Sapiens  'I', 'my' 
ICO:0000196 act of informed consenting 'I agree that' 
ICO:0000001 Informed consent form  Implicit 
ICO:0000244 Permission Directive Entire sentence 
OBI:0000659 Specimen Collection Process 'removed from my body' 
OBI:0100051 Specimen 'tissue, fluids or specimens' 
LABO:0000107 Laboratory Test 
Implicit in process by which a specimen becomes a 
residual clinical biospecimen 
OGMS:0000018 Laboratory Finding 
Implicit in process by which a specimen becomes a 
residual clinical biospecimen 
ICO:0000313 Excess Material Role 'excess tissue, fluids or specimens' 
-- Residual clinical biospecimen 'excess tissue, fluids or specimens' 
OMRSE:00002029 education process 'educational purposes' 
OBI:0000066 Investigation 'research' 
DUO:0000038 genetic research 
'research, including research on the genetic 
materials (DNA).' 
Relations 
BFO:0000051 has part  
BFO:0000054 Realized in  
CommonCore 
Ontologies/prescribes prescribes  
OBI:0000295 is:specified:input:of  
RO:0000053 bearer of  
RO:0000056 Participates in  
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Table 30. Terms and Sentence References to Express the Permission-Sentence: “I authorize the pathologist, at his or her 
discretion, to retain, preserve, use, or dispose of any tissues, organs, bones, bodily fluid or medical devices that may be removed 
during the operation(s) or procedure(s).” 
I authorize the pathologist, at his or her discretion, to retain, preserve, use, or dispose of any tissues, organs, bones, 
bodily fluid or medical devices that may be removed during the operation(s) or procedure(s). 
Ontology PURL Ontology Label Sentence Reference 
Classes 
ICO:0000199 Permission Role 'I authorize the pathologist' 
OBI:0000093 Patient role 'removed during the operation(s) or procedure(s)' 
ICO:0000086 Consenter Role 'I authorize' 
OBI:0000145 Pathologist role 'the pathologist' 
NCBITaxon:9606 Homo Sapiens 'I', 'the pathologist' 
ICO:0000196 Act of Informed Consenting 'I authorize' 
ICO:0000001 Informed consent form Implicit 
ICO:0000244 Permission Directive Entire sentence 
OBI:0000659 Specimen Collection Process 'removed during the operation(s) or procedure(s)' 
OBI:0100051 Specimen 
'tissues, organs, bones, bodily fluid or medical 
devices' 
LABO:0000107 Laboratory Test 
Implicit in process by which a specimen becomes 
a residual clinical biospecimen 
OGMS:0000018 Laboratory Finding 
Implicit in process by which a specimen becomes 
a residual clinical biospecimen 
ICO:0000313 Excess Material Role 
Implicit in process by which a specimen becomes 
a residual clinical biospecimen 
-- Residual clinical biospecimen 
Implicit in process by which a specimen becomes 
a residual clinical biospecimen 
ICO:0000060 Act of storing a specimen 'to retain' 
NCIT:C64262 Biologic Sample Preservation Procedure 'preserve' 
NCIT:C95018 Use 'use' 
CHMO:0002832 Material disposal 'dispose' 
Relations 
BFO:0000051 has part  
BFO:0000054 Realized in  
CommonCore 
Ontologies/prescribes prescribes  
DUO:0000010 Is restricted to  
OBI:0000293 has:specified:input  
OBI:0000295 is:specified:input:of  
OBI:0000299 has:specified:output  
RO:0000053 bearer of  
RO:0000056 Participates in  
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Table 31. Terms and Sentence References to Express the Permission-Sentence: “I, , request and consent to the start or induction 
of my labor by my provider: and other assistants as may be selected by him/her.” 
I, , request and consent to the start or induction of my labor by my provider: and other assistants as may be selected 
by him/her. 
Ontology PURL Ontology Label Sentence Reference 
Classes 
ICO:0000199 Permission Role 'I, , request and consent... by my provider' 
OBI:0000093 Patient Role 'I', 'induction of my labor' 
ICO:0000086 Consenter Role 'I, , request and consent' 
OBI:0000207 health care provider role 'by my provider: and other assistants...' 
NCBITaxon:9606  Homo Sapiens  'I', 'my provider', 'assistants' 
OGMS:0000096 Health Care Process  'start or induction of my labor' 
ICO:0000196 act of informed consenting 'I, , request and consent' 
ICO:0000001 Informed consent form  Implicit 
ICO:0000244 Permission Directive Entire Sentence 
Relations 
BFO:0000051 has part  
BFO:0000054 Realized in  
CommonCore 
Ontologies/prescribes prescribes  
RO:0000053 bearer of  
RO:0000056 Participates in  
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Table 32. Terms and Sentence References to Express the Permission-Sentence: “I voluntarily consent to receive medical and 
health care services that may include diagnostic procedures, examination, and treatment.” 
I voluntarily consent to receive medical and health care services that may include diagnostic procedures, 
examination, and treatment. 
Ontology PURL Ontology Label Sentence Reference 
Classes 
ICO:0000086 Consenter Role 
'consent to receive medical and health care 
services' 
NCBITaxon:9606  Homo Sapiens  
'I', implicit health care provider(s) who 
provides the health services 
ICO:0000244 Permission Directive Entire Sentence 
ICO:0000196 act of informed consenting 'I voluntarily consent' 
ICO:0000001 Informed consent form  Implicit 
OGMS:0000096 Health Care Process  
'health care services that may include 
diagnostic procedures, examination, and 
treatment' 
OGMS:0000104 Diagnostic Process 'diagnostic procedures' 
OBI:0600003 performing a clinical assessment 'examination' 
OGMS:0000090 Treatment 'treatment' 
Relations 
BFO:0000051 has part  
BFO:0000054 Realized in  
CommonCore 
Ontologies/prescribes prescribes  
RO:0000053 bearer of  
RO:0000056 Participates in  
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Table 33. Terms and Sentence References to Express the Permission-Sentence: “I consent to the use of closed-circuit television, 
taking of photographs (including videos), and the preparation of drawings and similar illustrative graphic material for scientific 
purposes providing my identity is not revealed.” 
I consent to the use of closed-circuit television, taking of photographs (including videos), and the preparation of 
drawings and similar illustrative graphic material for scientific purposes providing my identity is not revealed. 
Ontology PURL Ontology Label Sentence Reference 
Classes 
ICO:0000199 Permission Role 'consent to the use of' 
OBI:0000093 Patient Role 
'I', inferred from context of clinical consent 
form 
ICO:0000086 Consenter Role 'I consent to' 
NCBITaxon:9606  Homo Sapiens  
I', implicit person(s) who take the photos, 
videos, etc. 
ICO:0000196 act of informed consenting 'I consent to' 
ICO:0000001 Informed consent form  Implicit 
ICO:0000244 Permission Directive Entire Sentence 
IAO:0000572 Documenting 
'use of closed-circuit television, taking of 
photographs (including videos), and the 
preparation of drawings and similar 
illustrative graphic material' 
BFO:0000040 Material Entity 
'photographs', 'videos', 'illustrative graphic 
material' 
IAO:0000030 Information Content Entity 
'photographs', 'videos', 'illustrative graphic 
material' 
IAO:0000185 Photograph 'photographs' 
ERO:0000333 Video 'videos' 
FBbi:00000223 Graphic Illustration 'illustrative graphic material' 
DUO:0000001 Data Use Limitation 
'for scientific purposes providing my 
identity is not revealed' 
OBI:0000066 Investigation 'scientific purposes' 
ICO:0000218 Act of Removing Identifiable Information providing my identity is not revealed' 
Relations 
BFO:0000051 has part  
BFO:0000054 Realized in  
CommonCore 
Ontologies/prescribes prescribes  
OBI:0000295 is:specified:input:of  
OBI:0000299 has:specified:output  
RO:0000053 bearer of  
RO:0000056 Participates in  
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Table 34. Terms and Sentence References to Express the Permission-Sentence: “I hereby consent to engaging in virtual 
health/telemedicine services, where available, as part of my treatment.” 
I hereby consent to engaging in virtual health/telemedicine services, where available, as part of my treatment. 
Ontology PURL Ontology Label Sentence Reference 
Classes 
ICO:0000086 Consenter Role 
'hereby consent to engaging in virtual 
health/telemedicine services' 
NCBITaxon:9606  Homo Sapiens  
'I', implicit person(s) are providing telehealth 
services 
ICO:0000244 Permission Directive Entire Sentence 
ICO:0000196 act of informed consenting 'I hereby consent to' 
ICO:0000001 Informed consent form  Implicit 
NCIT:C15380 Telemedicine 'virtual health/telemedicine services' 
Relations 
BFO:0000051 has part  
BFO:0000054 Realized in  
CommonCore 
Ontologies/prescribes prescribes  
RO:0000053 bearer of  
RO:0000056 Participates in  
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Table 35. Terms and Sentence References to Express the Permission-Sentence: “I request and authorize URMC Labs to perform 
only the above designated test(s) on the sample from me (or my child or fetus).” 
I request and authorize URMC Labs to perform only the above designated test(s) on the sample from me (or my 
child or fetus). 
Ontology PURL Ontology Label Sentence Reference 
Classes 
ICO:0000199 Permission Role 'request and authorize URMC Labs' 
ICO:0000086 Consenter Role 'I request and authorize' 
OBI:0000245 Organization 'URMC Labs' 
NCBITaxon:9606  Homo Sapiens  'I', 'sample from me (or my child or fetus)' 
ICO:0000244 Permission Directive Entire Sentence 
LABO:0000107 Laboratory Test 'perform only the above designated test(s)' 
ICO:0000196 act of informed consenting 'I request and authorize' 
ICO:0000001 Informed consent form  Implicit 
NCIT:C16423 Child 'child' 
NCIT:C13235 Fetus 'fetus' 
Relations 
BFO:0000051 has part  
BFO:0000054 Realized in  
CommonCore 
Ontologies/prescribes prescribes  
RO:0000053 bearer of  
RO:0000056 Participates in  
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